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2 
AMPHIPATHIC ALPHA-HELICAL PEPTIDE 
COMPOSITIONS AS ANTIVIRAL AGENTS 
FEDERALLY-SPONSORED RESEARCH OR 
DEVELOPMENT 
This invention was made with Government support under 
contracts NAGS-1843 awarded by NASA aid DK064223 
awarded by the National Institutes of Health. The Govern-
ment has certain rights in this invention. 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority to U.S. Provisional Patent 
Application No. 60/961,457 filed Jul. 19, 2007, and to U.S. 
Provisional Patent Application No. 61/080,210 filed Jul. 11, 
2008, which applications are incorporated herein by refer-
ence in their entirety and for all purposes. 
BACKGROUND 
HCV is an enveloped positive strand RNA virus. The single 
strand HCV RNA genome is approximately 9500 nucleotides 
in length and has a single open reading frame (ORE) encoding 
a single large polyprotein of about 3000 amino acids. In 
infected cells, this polyprotein is cleaved at multiple sites by 
cellular and viral proteases to produce structural and non-
structural (NS) proteins. In the case of HCV, the generation of 
mature nonstructural proteins (NS2, NS3, NS4A, NS413, 
NS5A, and NS513) is effected by two viral proteases. The first 
one is a metalloprotease located in NS2 that cleaves the 
NS2-NS3 junction in cis; the second one is a serine protease 
contained within the N-terminal region of NS3 (henceforth 
referred to as NS3 protease) and mediates all the subsequent 
cleavages downstream of NS3, both in cis, at the NS3-NS4A 
cleavage site, and in trans, at the remaining NS4A-NS4B, 
NS4B-NS5A, NS5A-NS5B sites. The NS4A protein appears 
to serve multiple functions, acting as a cofactor for the NS3 
protease and possibly assisting in the membrane localization 
of NS3 and other viral replicase components. 
Among the viral non-structural proteins is NS5A. Inspec-
tion of NS5A's amino acid sequence revealed the predicted 
presence of an amphipathic a-helix (AH) at the NH z-termi-
nus. This AH is necessary and sufficient for mediating mem-
brane association of NS5A and has been proposed to anchor 
the protein by insertion of the helix within the plane of the 
membrane. Evidence for a host-cell membrane protein recep-
tor has recently been reported. Genetic disruption of the 
NS5AAH abrogates NS5A membrane association, and HCV 
RNA replication is halted. 
SUMMARY OF THE INVENTION 
The invention features methods and compositions that 
exploit the ability of amphipathic alpha-helical (AH) peptides 
to cause disruption of lipid-containing vesicles, such as envel-
oped viruses, in a size-dependent manner. 
Accordingly, in some aspects the disclosure provides 
methods of inactivating an enveloped virus, the method com-
prising contacting an enveloped virus having an average par-
ticle diameter of less than 250 nm with an amphipathic alpha-
helical (AH) peptide in an amount and under conditions 
effective to facilitate disruption of the viral envelope, with the 
proviso that the enveloped virus is other than hepatitis C virus 
(HCV), wherein said contacting is effective to disrupt the 
viral envelope of the virus, thereby reducing infectivity of the 
virus. In related embodiments, the enveloped virus is present 
in a biological fluid, such as blood, and may be extracorpo-
real. 
Examples of conditions effective to facilitate disruption of 
5 the viral envelope include a pH of 7.5 or less, a pH of 7.0 or 
less, a pH of 6.5 or less, a pH of 5.0 or less, a pH of 5.5 or less, 
a pH of 5.0 or less, a pH of 4.5 or less, or a pH of 4.0 or less. 
In additional examples, conditions effective to facilitate 
disruption of the viral envelope include a temperature of 20° 
10 C. or greater, 25° C. or greater, or 30° C. or greater. 
Conditions effective to facilitate disruption of the viral 
envelope can also include can also include contacting the 
enveloped virus with the AH peptide in a solution with a 
solute concentration greater than that found in the enveloped 
15 VlrUS. 
In related embodiments, the disclosure provides methods 
for treating in vitro or ex vivo biological fluid, comprising 
contacting an isolated biological fluid with an effective 
amount of an amphipathic alpha-helical (AH) peptide 
20 wherein said contacting provides for disruption of an envel-
oped virus that may be present in the biological fluid. In some 
embodiments, the enveloped virus has an average particle 
diameter of less then 250 mu and is other than hepatitis C 
virus. In related embodiments, contacting is accomplished by 
25 mixing the biological fluid with a composition comprising the 
AH peptide. In related embodiments, the AH peptide is 
immobilized on a surface of a substrate. 
The disclosure also provide methods for treating a subject 
having, suspected of having, or susceptible to infection by a 
30 enveloped virus, the method comprising administering an 
amphipathic a-helical (AH) peptide to a subject in need 
thereof and having, suspected of having, or susceptible to 
infection by a enveloped virus other than hepatitis C virus, 
wherein said AH peptide is administered in an amount effec- 
35 tive to facilitate disruption of an envelope of an enveloped 
virus that may be present in the subject or to which the subject 
may have been or may be exposed. 
The disclosure further provides methods for treating a non-
human subject having, suspected of having, or susceptible to 
40 infection by a enveloped virus, the method comprising: 
administering an amphipathic a-helical (AH) peptide to a 
non-human subject in need thereof and having, suspected of 
having, or susceptible to infection by a enveloped virus, 
wherein said AH peptide is administered in an amount effec- 
45 tive to facilitate disruption of an envelope of an enveloped 
virus that may be present in the subject or to which the subject 
may have been or may be exposed. 
Also provided are methods for decreasing a level of an 
enveloped virus contaminating a material, the method com- 
50 prising treating a material with an effective amount of an 
amphipathic a-helical (AH) peptide, wherein said treating is 
effective to disrupt at least 25% of enveloped viral particles 
that may be associated with the material, wherein the envel-
oped virus has an average particle diameter of less then 250 
55 mu and is other than hepatitis C virus. The material can be a 
biological fluid (such as blood or a blood product) or biologi-
cal tissue (e.g., an organ for transplant), and may be present in 
a container. The methods can further comprise removing all 
or a portion of the AH peptide and/or disrupted enveloped 
60 viral particle from the material after treating. 
The disclosure also provides substrates comprising at least 
a surface treated with an amphipathic alpha-helical (AH) 
peptide. The substrate can be, for example, a biological fluid 
container (e.g., a blood donation bag or bottle), a medical 
65 device (e.g., a an in-line filter through which blood or blood 
product is passed prior to delivery to an individual or through 
which blood or blood product is passed at the point of collec- 
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tion from an individual), or any variety of other substrates 	 solution was added (0.05 mg/ml) to the intact vesicles (0100 
(e.g., a filter, tubing, seal, clamp, transfer leg closure, operat- 	 nm PEC-148 nm±1.4 mu) on the gold surface. The peptide 
ing table, or medical examination table). Optionally, the AH 	 destabilized and ruptured the vesicles, but did not make a 
peptide is immobilized to a surface of the substrate. 	 complete bilayer. After 340 min (arrow 5), two buffer washes 
The disclosure further provides disinfectant compositions 5 were performed and the stability of the bilayers on the gold 
comprising an amphipathic a-helical (AH) peptide and at 	 surface was observed. 
least one component that is not pharmaceutically acceptable 	 FIG. 5, Panels (a-e): Change in QCM resonant frequency 
for human administration. 	 and dissipation as a function of time for novel bilayer fonna- 
Other aspects and embodiments will be readily apparent to 	 tion process on TiO 2 surface. (030 nm PEC-59 nrn±0.2 mu, 
the ordinarily skilled artisan upon reading the present speci- 10 0100 mu PEC-148 mut 14 mu) (Panel a) Af(t) (blue curve) 
fication. 	 and AD(t) (red curve) show vesicle adsorption on a TiO 2 
surface. After 10 min (first arrow) of stabilizing the frequency 
BRIEF DESCRIPTION OF THE DRAWINGS 	 signal, the POPC vesicle solution (030 nm PEC) was applied 
to the liquid cell. After 60 min (second arrow), two buffer 
FIG. 1, Panels a-c: Schematic representations of the 15 washes were performed and the stability of the intact vesicles 
amphipathic alpha helix (AH) (FIG. 1, panel a) and non- 	 on the TiO2 surface was observed. (Panel b) After 55 min 
amphipathic, non-helical (NH) (FIG. 1, Panel b) peptides, 	 (arrow 4), the amphipathic a-helical AH peptide solution was 
and proposed schematic of creating bilayer on An and TiO 2 	 added (0.05 mg/ml) to the intact vesicles (030 nm PEC) on 
(FIG. 1, panel c). 	 the TiO2 surface. The AH peptide destabilized and ruptured 
FIG. 2 provides the results of an analysis of the rupturing 20 the vesicles, making a complete bilayer. In (Panel c), the 
and fusion process of bilayer formation from vesicles on An 	 effect of the NH peptide was examined in a similar manner to 
(Panel 2-1) and TiO2 (Panel 2-2) by QCM-D andAFM. Panel 	 that done with the AH peptide in Panel b. After 10 min (arrow 
2-1, sub-panels a-c, show the change in QCM resonant fre- 	 1) of stabilizing the frequency signal, the POPC vesicle solu- 
quency and dissipation as a function of time for novel bilayer 	 tion (030 nm PEC) was applied to the liquid cell. After 40 and 
formation process on gold surface. (Sub-panel a) Af(t) (blue 25 50 min (arrows 2 and 3), two washes with the same buffer 
curve) and AD(t) (red curve) show vesicle adsorption on 	 were performed and the stability of the intact vesicles on the 
oxidized gold surface. After 10 min (arrow 1) of stabilizing 	 TiO2 surface was observed. At 60 min (arrow 4), the non- 
frequency signal, POPC vesicle solution was injected into the 	 amphipathic a-helix peptide (NH peptide) solution was 
liquid cell. After 50 and 55 min (arrows 2 and 3), the same 	 added (0.05 mg/ml) to the intact vesicles on the TiO 2 surface. 
buffer was used for two washes. (Sub-panel b) At 60 min 30 The NH peptide does not show any evidence of destabilizing 
(arrow 4), the amphipathic a-helix peptide (AH peptide) 	 and rupturing the vesicles. After 270 min (arrow 5), two 
solution was added (0.05 mg/ml) to the intact vesicles on the 	 buffer washes were performed and the stability of the intact 
gold surface. After 120 and 140 min (arrows 5 and 6), the 	 vesicle bilayers on the TiO 2 surface was observed. (Panel d): 
same buffer was used for two washes and the stability of the 	 In order to study the rupturing strength of the AH peptide, we 
bilayers on the gold surface was observed. (Sub-panel c) The 35 performed a similar test as in FIG. 2, panel 2-2, (sub-panel b), 
effect of the NH peptide was studied in an analogous manner 	 but added a larger size POPC vesicle solution (0 100 nm PEC) 
to the AH peptide as described for FIG. 2, panel 2-1, sub- 	 to the TiO2 surface. (Panel e): After 60 min (arrow 4), the 
panel (b). Panel 2-1, sub-panels d-f, show AFM images dem- 	 amphipathic a-helix peptide (AH peptide) solution was 
onstrating intact vesicles rupturing and spreading after addi- 	 added (0.05 mg/ml) to the intact vesicles on the TiO 2 surface. 
tion ofAH peptide onAu surface. The images are presented in 40 The peptide destabilized and ruptured the vesicles, but did not 
the Height mode. (Sub-panel d) Bare An surface. (Sub-panel 	 make a complete bilayer. 
e) Vesicles (0.1 mg/ml) deposited on An surface. (Sub-panel 	 FIG. 6, Panels (a-c) show AFM images demonstrating 
f) After treatment with the AH peptide (0.05 mg/ml). FIG. 2, 	 intact vesicles rupturing and spreading after addition of AH 
Panel 2-2, shows analogous experiments to FIG. 2, panel 2-1, 	 a-helical peptide on a TiO 2 surface. The images, collected in 
except performed on a TiO 2 surface. 	 45 buffer (150 mM NaCl, 10 mM Tris [pH 7.5], 1 mM EDTA), 
FIG. 3 shows a reprint and magnification of the AH binding 	 are presented in the height mode. All scan sizes are 2x2 µm 
kinetics of FIG. 2, panel 2-1, sub-panel (b). The blue high- 	 and the arrows along the side of the frames in FIG. 6, panel a, 
lighted portion on the left panel is enlarged to demonstrate 	 indicate the slow scan direction. (Panel a): Bare TiO 2 surface. 
binding ofAH peptide on the adsorbed vesicle layer. The high 
	 (Panel b): Vesicles (0.1 mg/ml) deposited on TiO 2 surface. 
frequency change is due to expansion of the vesicles (-30% 50 (Panel c): After treatment with AH peptide (0.05 mg/ml), the 
change in mass), which is followed by AH peptide-induced 	 AFM image demonstrated that some vesicles form a bilayer 
vesicle destabilization and rupture, withresulting loss of lipid 	 as a result of treatment ofAH Peptide after 120 min. However, 
mass upon bilayer formation. The corresponding high energy 	 vesicles were not ruptured completely within 3 hours. Only 
dissipation change is due to expansion of vesicles as well as 	 100 to 200 nm hyperbola-shaped objects were counted as 
the formation of finger-like microvilli structures. 	 55 vesicles. 
FIG. 4: Change in QCM resonant frequency and dissipa- 	 FIG. 7 provides a graph which shows the effect of 
tion as a function of time for novel bilayer formation process 	 increased temperature on the efficiency of AH peptide medi- 
on gold surface (0100 nm PEC=148 nm±1.4 nm) Panel (a): In 	 ated vesicle lysis. 
order to study the rupturing strength of the AH peptide, a 	 FIG. 8 provides a graph which shows the effect of altering 
similar test as in FIG. 2, Panel 2-1, sub-panel (a), using larger 60 the lipid composition of vesicles on the efficiency of AH 
vesicles (0100 nm PEC-148 nm±1.4 nm) was performed. 	 peptide mediated vesicle lysis. 
After 10 min (arrow 1) of stabilizing the frequency signal, the 	 FIG. 9 provides a graph which shows the effect of 
POPC vesicle solution (0.1 mg/ml) was injected into the 	 decreased pH on the efficiency of AH peptide mediated 
liquid cell. After 60 and 70 min (arrows 2 and 3), the same 	 vesicle lysis. 
buffer was used for two washes and the stability of the intact 65 	 FIG. 10 provides a graph which shows the effect of 
vesicles on the gold surface was observed. Panel (b): At 80 	 increased osmotic pressure between leaflets of vesicles on the 
min (arrow 4), the amphipathic a-helix peptide (AH peptide) 	 efficiency of AH peptide mediated vesicle lysis. 
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FIG. 11 provides a graph which shows the results of infec-
tivity assays for HCV and Vaccinia virus inoculums treated 
with AH or NH peptide. 
FIG. 12 shows the frequency response for various vesicle 
size distributions up to 100 nm uponAH peptide addition (A), 5 
corresponding energy dissipation changes (B), QCM fre-
quency response for vesicle size distribution greater than 100 
mu uponAH peptide addition (C), and corresponding energy 
dissipation changes (D). 
FIG. 13 shows a calculation of rupture potency from the 10 
frequency response using Sauerbrey equation from FIG. 12, 
Panels A and C. 
DEFINITIONS 
15 
Before the present invention is further described, it is to be 
understood that this invention is not limited to particular 
embodiments described, as such may, of course, vary. It is 
also to be understood that the terminology used herein is for 
the purpose of describing particular embodiments only, and is 20 
not intended to be limiting, since the scope of the present 
invention will be limited only by the appended claims. 
Where a range of values is provided, it is understood that 
each intervening value, to the tenth of the unit of the lower 
limit unless the context clearly dictates otherwise, between 25 
the upper and lower limit of that range and any other stated or 
intervening value in that stated range, is encompassed within 
the invention. The upper and lower limits of these smaller 
ranges may independently be included in the smaller ranges, 
and are also encompassed within the invention, subject to any 30 
specifically excluded limit in the stated range. Where the 
stated range includes one or both of the limits, ranges exclud-
ing either or both of those included limits are also included in 
the invention. 
Unless defined otherwise, all technical and scientific terms 35 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
belongs. Although any methods and materials similar or 
equivalent to those described herein can also be used in the 
practice or testing of the present invention, the preferred 40 
methods and materials are now described. All publications 
mentioned herein are incorporated herein by reference to 
disclose and describe the methods and/or materials in con-
nection with which the publications are cited. 
It must be noted that as used herein and in the appended 45 
claims, the singular forms "a", "and", and "the" includeplural 
referents unless the context clearly dictates otherwise. Thus, 
for example, reference to "a peptide" includes a plurality of 
such peptides and reference to "agent' includes reference to 
one or more agents and equivalents thereof known to those 50 
skilled in the art, and so forth. 
The publications discussed herein are provided solely for 
their disclosure prior to the filing date of the present applica-
tion. Nothing herein is to be construed as an admission that 
the present invention is not entitled to antedate such publica- 55 
tion by virtue of prior invention. Further, the dates of publi-
cation provided may be different from the actual publication 
dates which may need to be independently confirmed. 
The term "amphipathic alpha-helix" or `AH" as used in the 
context of the present invention refers to a peptide structure 60 
containing both hydrophilic and hydrophobic residues such 
that one "side" of the alpha-helix is hydrophobic (e.g., due to 
the presence of Trp or other hydrophobic residues) and the 
"side" "opposite" the hydrophobic side is a hydrophilic, 
charged side. 65 
The terms "polypeptide" and "protein", used interchange-
ably herein, refer to a polymeric form of amino acids of any  
6 
length, which can include coded and non-coded amino acids, 
chemically or biochemically modified or derivatized amino 
acids, and polypeptides having modified peptide backbones. 
The term includes fusion proteins, including, but not limited 
to, fusion proteins with a heterologous amino acid sequence, 
fusions with heterologous and native leader sequences, with 
or without N-terminal methionine residues; immunologically 
tagged proteins; fusion proteins with detectable fusion part-
ners, e.g., fusion proteins including as a fusion partner a 
fluorescent protein, (3-galactosidase, luciferase, etc.; and the 
like. 
The terms "nucleic acid molecule" and "polynucleotide" 
are used interchangeably and refer to a polymeric form of 
nucleotides of any length, either deoxyribonucleotides or 
ribonucleotides, or analogs thereof. Polynucleotides may 
have any three-dimensional structure, and may perform any 
function, known or unknown. Non-limiting examples of 
polynucleotides include a gene, a gene fragment, exons, 
introns, messenger RNA (mRNA), transfer RNA, ribosomal 
RNA, ribozymes, cDNA, recombinant polynucleotides, 
branched polynucleotides, plasmids, vectors, isolated DNA 
of any sequence, control regions, isolated RNA of any 
sequence, nucleic acid probes, and primers. The nucleic acid 
molecule may be linear or circular. 
A "substitution" results from the replacement of one or 
more amino acids or nucleotides by different amino acids or 
nucleotides, respectively as compared to an amino acid 
sequence or nucleotide sequence of a polypeptide. If a sub-
stitution is conservative, the amino acid that is substituted into 
a polypeptide has similar structural or chemical properties 
(e.g., charge, polarity, hydrophobicity, and the like) to the 
amino acid that it is substituting. Conservative substitutions 
of naturally occurring amino acids usually result in a substi-
tution of a first amino acid with second amino acid from the 
same group as the first amino acid, where exemplary amino 
acid groups are as follows: (1) acidic (negatively charged) 
amino acids such as aspartic acid and glutamic acid; (2) basic 
(positively charged) amino acids such as arginine, histidine, 
and lysine; (3) neutral polar amino acids such as glycine, 
serine, threonine, cysteine, cystine, tyrosine, asparagine, and 
glutamine; and (4) neutral non-polar amino acids such as 
alanine, leucine, isoleucine, valine, proline, phenylalanine, 
tryptophan, and methionine. In some embodiments, polypep-
tide variants may have "non-conservative" changes, where 
the substituted amino acid differs in structural and/or chemi-
cal properties. 
A "deletion" is defined as a change in either amino acid or 
nucleotide sequence in which one or more amino acid or 
nucleotide residues, respectively, are absent as compared to 
an amino acid sequence or nucleotide sequence of a naturally 
occurring polypeptide. In the context of a polypeptide or 
polynucleotide sequence, a deletion can involve deletion of 2, 
5, 10, up to 20, up to 30 or up to 50 or more amino acids, 
taking into account the length of the polypeptide or poly-
nucleotide sequence being modified. 
An "insertion" or "addition" is that change in an amino acid 
or nucleotide sequence which has resulted in the addition of 
one or more amino acid or nucleotide residues, respectively, 
as compared to an amino acid sequence or nucleotide 
sequence of a naturally occurring polypeptide. "Insertion" 
generally refers to addition to one or more amino acid resi-
dues within an amino acid sequence of a polypeptide, while 
"addition" can be an insertion or refer to amino acid residues 
added at the N- or C-termini. In the context of a polypeptide 
or polynucleotide sequence, an insertion or addition may be 
of up to 10, up to 20, up to 30 or up to 50 or more amino acids. 
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"Non-native", "non-endogenous", and "heterologous", in 
the context of a polypeptide, are used interchangeably herein 
to refer to a polypeptide having an amino acid sequence or, in 
the context of an expression system or a viral particle, present 
in an environment different to that found in nature. 
"Exogenous" in the context of a nucleic acid orpolypeptide 
is used to refer to a nucleic acid or polypeptide that has been 
introduced into a host cell. "Exogenous" nucleic acids and 
polypeptides can be native or non-native to the host cell, 
where an exogenous, native nucleic acid or polypeptide pro-
vides for elevated levels of the encoded gene product or 
polypeptide in the recombinant host cell relative to that found 
in the host cell prior to introduction of the exogenous mol-
ecule. 
As used herein, the terms "determining," "measuring," 
"assessing," and "assaying" are used interchangeably and 
include both quantitative and qualitative determinations. 
As used herein the term "isolated," when used in the con-
text of an isolated compound, refers to a compound of interest 
that is in an environment different from that in which the 
compound naturally occurs. "Isolated" is meant to include 
compounds that are within samples that are substantially 
enriched for the compound of interest and/or in which the 
compound of interest is partially or substantially purified. 
As used herein, the term "substantially pure" refers to a 
compound that is removed from its natural environment and is 
at least 60% free, preferably 75% free, and most preferably 
90% free from other components with which it is naturally 
associated. 
A "coding sequence" or a sequence that "encodes" a 
selected polypeptide, is a nucleic acid molecule which is 
transcribed (in the case of DNA) and translated (in the case of 
mRNA) into a polypeptide, for example, in-vivo when placed 
under the control of appropriate regulatory sequences (or 
"control elements"). The boundaries of the coding sequence 
are typically determined by a start codon at the 5' (amino) 
terminus and a translation stop codon at the 3' (carboxy) 
terminus. A coding sequence can include, but is not limited to, 
cDNA from viral, prokaryotic or eukaryotic mRNA, genomic 
DNA sequences from viral or prokaryotic DNA, and syn-
thetic DNA sequences. A transcription termination sequence 
may be located 3' to the coding sequence. Other "control 
elements" may also be associated with a coding sequence. A 
DNA sequence encoding a polypeptide can be optimized for 
expression in a selected cell by using the codons preferred by 
the selected cell to represent the DNA copy of the desired 
polypeptide coding sequence. 
"Encoded by" refers to a nucleic acid sequence which 
codes for a gene product, such as a polypeptide. Where the 
gene product is a polypeptide, the polypeptide sequence or a 
portion thereof contains an amino acid sequence of at least 3 
to 5 amino acids, more preferably at least 8 to 10 amino acids, 
and even more preferably at least 15 to 20 amino acids from 
a polypeptide encoded by the nucleic acid sequence. 
"Operably linked" refers to an arrangement of elements 
wherein the components so described are configured so as to 
perform their usual function. In the case of a promoter, a 
promoter that is operably linked to a coding sequence will 
effect the expression of a coding sequence. The promoter or 
other control elements need not be contiguous with the cod-
ing sequence, so long as they function to direct the expression 
thereof. For example, intervening untranslated yet tran-
scribed sequences can be present between the promoter 
sequence and the coding sequence and the promoter sequence 
can still be considered "operably linked" to the coding 
sequence. 
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By "nucleic acid construct" it is meant a nucleic acid 
sequence that has been constructed to comprise one or more 
functional units not found together in nature. Examples 
include circular, linear, double-stranded, extrachromosomal 
5 DNA molecules (plasmids), cosmids (plasmids containing 
COS sequences from lambda phage), viral genomes compris-
ing non-native nucleic acid sequences, and the like. 
A "vector" is capable of transferring gene sequences to 
target cells. Typically, "vector construct," "expression vec- 
io tor," and "gene transfer vector," mean any nucleic acid con-
struct capable of directing the expression of a gene of interest 
and which can transfer gene sequences to target cells, which 
can be accomplished by genomic integration of all or a por-
tion of the vector, or transient or inheritable maintenance of 
15 the vector as an extrachromosomal element. Thus, the term 
includes cloning, and expression vehicles, as well as integrat-
ing vectors. 
An "expression cassette" comprises any nucleic acid con-
struct capable of directing the expression of a gene/coding 
20 sequence of interest, which is operably linked to a promoter 
of the expression cassette. Such cassettes can be constructed 
into a "vector," "vector construct," "expression vector," or 
"gene transfer vector," in order to transfer the expression 
cassette into target cells. Thus, the term includes cloning and 
25 expression vehicles, as well as viral vectors. 
Techniques for determining nucleic acid and amino acid 
"sequence identity" are known in the art. Typically, such 
techniques include determining the nucleotide sequence of 
the mRNA for a gene and/or determining the amino acid 
30 sequence encoded thereby, and comparing these sequences to 
a second nucleotide or amino acid sequence. In general, 
"identity" refers to an exact nucleotide-to-nucleotide or 
amino acid-to-amino acid correspondence of two polynucle-
otides or polypeptide sequences, respectively. Two or more 
35 sequences (polynucleotide or amino acid) can be compared 
by determining their "percent identity." The percent identity 
of two sequences, whether nucleic acid or amino acid 
sequences, is the number of exact matches between two 
aligned sequences divided by the length of the shorter 
40 sequences and multiplied by 100. An approximate alignment 
for nucleic acid sequences is provided by the local homology 
algorithm of Smith and Waterman, Advances in Applied 
Mathematics 2:482-489 (1981). This algorithm can be 
applied to amino acid sequences by using the scoring matrix 
45 developed by Dayhoff, Atlas of Protein Sequences and Struc-
ture, M. O. Dayhoff ed., 5 suppl. 3:353-358, National Bio-
medical Research Foundation, Washington, D.C., USA, and 
normalized by Gribskov, Nucl. Acids Res. 14 (6):6745-6763 
(1986). 
50 An exemplary implementation of this algorithm to deter-
mine percent identity of a sequence is provided by the Genet-
ics Computer Group (Madison, Wis.) in the `BestFit" utility 
application. The default parameters for this method are 
described in the Wisconsin Sequence Analysis Package Pro- 
55 gram Manual, Version 8 (1995) (available from Genetics 
Computer Group, Madison, Wis.). A preferred method of 
establishing percent identity in the context of the present 
invention is to use the MPSRCH package of programs copy-
righted by the University of Edinburgh, developed by John F. 
60 Collins and Shane S. Sturrok, and distributed by IntelliGe-
netics, Inc. (Mountain View, Calif.). From this suite of pack-
ages the Smith-Waterman algorithm can be employed where 
default parameters are used for the scoring table (for example, 
gap open penalty of 12, gap extension penalty of one, and a 
65 gap of six). From the data generated the "Match" value 
reflects "sequence identity." Other suitable programs for cal-
culating the percent identity or similarity between sequences 
US 8,728,793 B2 
9 
are generally known in the art, for example, another align-
ment program is BLAST, used with default parameters. For 
example, BLASTN and BLASTP can be used using the fol-
lowing default parameters: genetic code —standard; 
filter=none; strand=both; cutof =60; expect=10; 5 
Matrix=BLOSUM62; Descriptions-50 sequences; sort 
by=HIGH SCORE; Databases=non-redundant, GenBank+ 
EMBL+DDB7+PDB+GenBank CDS translations+Swiss 
protein+Spupdate+PIR. Details of these programs can be 
found at the internet address located by placing http://www  in io 
front of .ncbi.nlm.gov/cgi-bin/BLAST. 
Alternatively, homology can be determined by hybridiza-
tion of polynucleotides under conditions that form stable 
duplexes between homologous regions, followed by diges-
tion with single-stranded-specific nuclease(s), and size deter- 15 
mination of the digested fragments. Two DNA, or two 
polypeptide sequences are "substantially homologous" to 
each other when the sequences exhibit at least about 80%-
85%, preferably at least about 85%-90%, more preferably at 
least about 90%-95%, and most preferably at least about 20 
95%-98% sequence identity over a defined length of the 
molecules, as determined using the methods above. As used 
herein, substantially homologous also refers to sequences 
showing complete identity to the specified DNA or polypep-
tide sequence. DNA sequences that are substantially homolo- 25 
gous can be identified in a Southern hybridization experiment 
under, for example, stringent conditions, as defined for that 
particular system. Defining appropriate hybridization condi-
tions is within the skill of the art. See, e.g., Sambrook et al., 
infra; DNA Cloning, supra; Nucleic Acid Hybridization, 30 
supra. 
A first polynucleotide is "derived from" a second poly-
nucleotide if it has the same or substantially the same nucle-
otide sequence as a region of the second polynucleotide, its 
cDNA, complements thereof, or if it displays sequence iden- 35 
tity as described above. This term is not meant to require or 
imply the polynucleotide must be obtained from the origin 
cited (although such is encompassed), but rather can be made 
by any suitable method. 
A first polypeptide (or peptide) is "derived from" a second 40 
polypeptide (or peptide) if it is (i) encoded by a first poly-
nucleotide derived from a second polynucleotide, or (ii) dis-
plays sequence identity to the second polypeptides as 
described above. This term is not meant to require or imply 
the polypeptide must be obtained from the origin cited (al- 45 
though such is encompassed), but rather can be made by any 
suitable method. 
The term "in combination with" as used herein refers to 
uses where, for example, a first therapy is administered during 
the entire course of administration of a second therapy; where 50 
the first therapy is administered for a period of time that is 
overlapping with the administration of the second therapy, 
e.g. where administration of the first therapy begins before the 
administration of the second therapy and the administration 
of the first therapy ends before the administration of the 55 
second therapy ends; where the administration of the second 
therapy begins before the administration of the first therapy 
and the administration of the second therapy ends before the 
administration of the first therapy ends; where the adminis-
tration of the first therapy begins before administration of the 60 
second therapy begins and the administration of the second 
therapy ends before the administration of the first therapy 
ends; where the administration of the second therapy begins 
before administration of the first therapy begins and the 
administration of the first therapy ends before the adminis- 65 
tration of the second therapy ends. As such, "in combination" 
can also refer to regimen involving administration of two or  
10 
more therapies. "In combination with" as used herein also 
refers to administration of two or more therapies which may 
be administered in the same or different formulations, by the 
same or different routes, and in the same or different dosage 
form type. 
The terms "treatment', "treating", "treat', and the like, 
referto obtaining a desired pharmacologic and/or physiologic 
effect. The effect may be prophylactic in terms of completely 
or partially preventing a disease or symptom thereof and/or 
may be therapeutic in terms of a partial or complete cure for 
a disease and/or adverse affect attributable to the disease. 
"Treatment", as used herein, covers any treatment of a disease 
in a mammal, particularly in a human, and includes: (a) pre-
venting the disease from occurring in a subject which may be 
predisposed to the disease but has not yet been diagnosed as 
having it; (b) inhibiting the disease, i.e., arresting its devel-
opment or progression; and (c) relieving the disease, i.e., 
causing regression of the disease and/orrelieving one ormore 
disease symptoms. "Treatment' is also meant to encompass 
delivery of an agent in order to provide for a phannacologic 
effect, even in the absence of a disease or condition. For 
example, "treatment' encompasses delivery of anAH peptide 
that can provide for reduction of viral load in an affected 
subject. 
"Subject", "host' and "patient' are used interchangeably 
herein, to refer to an animal, human or non-human, suscep-
tible to or having an infection by an enveloped pathogen, 
especially an enveloped virus, and amenable to therapy 
according to the methods of the invention. Generally, the 
subject is a mammalian subject, particularly a subject having, 
suspected of having, or at risk of a viral infection. The meth-
ods herein particularly contemplate treatment of a subject 
having, suspected of having, or at risk of a infection by a virus 
other than HCV. 
DETAILED DESCRIPTION OF EXEMPLARY 
EMBODIMENTS OF THE INVENTION 
The invention is based on the discovery that amphipathic 
alpha-helical (AH) peptides rupture lipid vesicles. The effi-
ciency of vesicle rupture mediated by AH peptides is affected 
by vesicle radius and line tension, with most efficient rupture 
occurring as the radius decreases and/or the line tension 
increases. This is postulated to reflect the increased line ten-
sion associated with vesicles of smaller radius. The range of 
vesicle size subj ect to rupture by the AH peptide encompasses 
the range of vesicle sizes of a significant number of viruses. 
Thus, the AH peptide is useful in destruction of viruses extra-
corporally (e.g., for prevention and disinfection) and within 
infected individuals (for therapy). 
AH Peptides 
AH peptides generally have an amino acid sequence based 
on an amphipathic a-helix of an HCV nonstructural (NS) 
protein selected from NSSA, NS413, NSSB, and NS4A, and 
facilitate disruption of an enveloped virus. Such AH peptides 
may contain a native (naturally-occurring) amino acid 
sequence of such NS proteins, including variants that occur in 
various different HCV genotypes. As describe din more detail 
below, AH peptides may also be based on such NS proteins, 
but contain conservative amino acid substitutions which 
maintain the amphipathic and a-helical nature of the native 
amino acid sequence. 
AH peptides can be of any suitable length, and usually are 
from about 14 to 30, about 15 to 25, about 16 to 20, about 17 
to 20, about 18 to 20 amino acids in length, and can be at least 
15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or30 
amino acids in length, with the proviso that the activity of the 
3a-NZL NS5A 4-27 WLRTIWDWVCSVLADFKAWLSAKI 
(SEQ ID NO. 	 17) 
3b NS5A 4-27 WLHDIWDWVCIVLSDFKTWLSAKI 
(SEQ ID NO. 	 18) 
4a NS5A 4-27 WLWDVWDWVLHVLSDFKTCLKAKF 
(SEQ ID NO. 	 19) 
10a NS5A 4-27 WLYDIVNWVCTVLADFKLWLGAKI 
(SEQ ID NO. 	 20) 
lla NS5A 4-27 WLRDIWDWVCTVLSDFRVWLKSKL 
(SEQ ID NO. 	 21) 
Further exemplary AH peptides based on NS5A include 
peptides having an amino acid sequence of: 
SWLRDVWDWICTVLTDFKTWLQSKL (SEQ ID NO: 22)  
SWLRDVWDWVCTILTDFKNWLTSKL (SEQ ID NO: 23)  
SWLRDIWEWVLSILTDFKNWLSAKL (SEQ ID NO: 24)  
SWLRIIWDWVCSWSDFKTWLSAKI (SEQ ID NO: 25)  
SWLRTIWDWVCSVLADFKAWLSAKI (SEQ ID NO: 26)  
SWLHDIWDWVCIVLSDFKTWLSAKI (SEQ ID NO: 27)  
SWLWDVWDWVLHVLSDFKTCLKAKF (SEQ ID NO: 28)  
SWLYDIVNWVCTVLADFKLWLGAKI (SEQ ID NO: 29)  
SWLRDIWDWVCTVLSDFRVWLKSKL (SEQ ID NO: 30)  
SGSLRDIWDWICEVLSDFKTWLKA (SEQ ID NO: 31)  
SGSWLRDVWDWICTVLTDFKTWLQSKL (SEQ ID NO: 32)  
SGSWLRDVWDWVCTILTDFKNWLTSKL (SEQ ID NO: 33)  
SGSWLRDIWEWVLSILTDFKNWLSAKL (SEQ ID NO: 34)  
SGSWLRIIWDWVCSWSDFKTWLSAKI (SEQ ID NO: 35)  
SGSWLRTIWDWVCSVLADFKAWLSAKI (SEQ ID NO: 36)  
SGSWLHDIWDWVCIVLSDFKTWLSAKI (SEQ ID NO: 37)  
SGSWLWDVWDWVLHVLSDFKTCLKAKF (SEQ ID NO: 38)  
SGSWLYDIVNWVCTVLADFKLWLGAKI (SEQ ID NO: 39)  
SGSWLRDIWDWVCTVLSDFRVWLKSKL (SEQ ID NO: 40)  
GSWLRDVWDWICTVLTDFKTWLQSKL (SEQ ID NO: 41)  
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peptide in viral envelope disruption is maintained. AH pep-
tides also include those that are no more than 30 amino acids, 
no more than 29, no more than 28 amino acids, no more than 
27 amino acids, no more than 26 amino acids, or no more than 
25 amino acids in length. AH peptides may be less than 60 
amino acids, less than 50 amino acids, less than 30 amino 
acids, orless than25 amino acids, withtheproviso thepeptide 
is at least about 15 amino acids in length. AH peptides may 
also be presented in the context of a larger polypeptide, such 
as a full-length HCV nonstructural polypeptide of NS5A, 
NS413, or NSSB or in a fusion polypeptide which contains an 
AH peptide linked to a heterologous polypeptide. 
Exemplary AH peptides include those having an amino 
acid sequence of the N-terminal amphipathic a-helix of the 
hepatitis C virus (HCV) nonstructural protein, NS5A. In gen-
eral such AH peptides contain an amino acid sequence of the 
formula: 
AH Peptides of NS5A 
NS 
5 	 Genotype Protein ResiduesAmino Acid Sequence 
la NS5A 5-26 	 LRDIWDWICEVLSDFKTWLKA 
(SED ID NO. 	 12) 
lb NS5A 4-27 	 WLRDVWDWICTVLTDFKTWLQSKL 
10 (SEQ ID NO. 	 13) 
2a NS5A 4-27 	 WLRDVWDWVCTILTDFKNWLTSKL 
(SEQ ID NO. 	 14) 
2b NS5A 4-27 	 WLRDIWEWVLSILTDFKNWLSAKL 
15 (SEQ ID NO. 	 15) 
3a-K NS5A 4-27 	 WLRIIWDWVCSVVSDFKTWLSAKI 
(SEQ ID NO. 	 16) 
SWLX 1X2X3X4X5WX6X7X$X9X 10 	 (SEQ ID NO: 1) 	 20 
wherein: 
X, is charged or polar residue, such as R, H, W, or Y, 
especially a positively charged residue such as R, K or H; 
Xz is any amino acid residue, and can be a residue other 
than an positively charged residue, e.g., D, I, or T, particularly 25 
negatively charged residue such as D or E; 
X3 is other than a charged residue, and can be a nonpolar 
(hydrophobic) residue, such as V or I; 
X4 is a nonpolar (hydrophobic) residue, such as W or V, 
Xs is a charged (e.g., negatively charged) or polar, 30 
uncharged residue, such as D, E, or N, particularly a nega-
tively charged residue such as D or E; 
X6 is other than a charged residue, and can be a nonpolar 
(hydrophobic) residue such as I or V, 
X, is polar, uncharged residue, nonpolar (hydrophobic) 35 
residue, or negatively charged residue, such as C or L or E, 
particularly a polar, uncharged residue, nonpolar (hydropho-
bic) residue, such as C or L; 
X$ is a polar, uncharged residue, a nonpolar (hydrophobic) 
residue, or a positively charged residue, such as T, S, I, or H, 40 
particularly a polar, uncharged residue such as T; 
Xg is a nonpolar (hydrophobic) residue, such as V, I or W; 
and 
X,, is C or L. 
Specific exemplary AH peptides having an exemplary for- 45 
mula of the above, are provided below: 
SWLRDVWDWICTVL 	 (SEQ ID NO: 2) 
50 
SWLRDVWDWVCTIL (SEQ ID NO: 3)  
SWLRDIWEWVLSIL (SEQ ID NO: 4)  
SWLRIIWDWVCSWC (SEQ ID NO: 5)  
SWLRTIWDWVCSVC (SEQ ID NO: 6) 55 
SWLHDIWDWVCIVC (SEQ ID NO: 7)  
SWLWDVWDWVLHVL (SEQ ID NO: 8)  
SWLYDIVNWVCTVC (SEQ ID NO: 9) 60 
SWLRDIWDWVCTVC (SEQ ID NO: 10)  
SWLRDIWDWICEVL (SEQ ID NO: 11)  
Exemplary amino acid sequences of NS5A- basedAH pep- 65 
tides include those having an amino acid sequence as set out 
below. 
US 8,728,793 B2 
(SEQ ID NO: 42; 
(SEQ ID NO: 43; 
(SEQ ID NO: 44; 
(SEQ ID NO: 45; 
(SEQ ID NO: 46; 
(SEQ ID NO: 47; 
(SEQ ID NO: 48; 
(SEQ ID NO: 49; 
(SEQ ID NO: 50; 
(SEQ ID NO: 51; 
(SEQ ID NO: 52; 
(SEQ ID NO: 53; 
(SEQ ID NO: 54; 
(SEQ ID NO: 55; 
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-continued 
GSWLRDVWDWVCTILTDFKNWLTSKL 
GSWLRDIWEWVLSILTDFKNWLSAKL 
GSWLRIIWDWVCSWSDFKTWLSAKI 
GSWLRTIWDWVCSVLADFKAWLSAKI 
GSWLHDIWDWVCIVLSDFKTWLSAKI 
GSWLWDVWDWVLHVLSDFKTCLKAKF 
GSWLYDIVNWVCTVLADFKLWLGAKI 
GSWLRDIWDWVCTVLSDFRVWLKSKL 
SWLRDVWDWICTVLT 
SWLRDVWDWVCTILT 
SWLRDIWEWVLSILT 
SWLRIIWDWVCSWSD 
SWLRTIWDWVCSVLA 
SWLHDIWDWVCIVLS 
14 
(D, E, and D, respectively), provide no sustained hydrophobic 
patch and resulted in a decrease in activity in vesicle disrup-
tion. 
Further exemplary AH peptides include peptides having an 
5 
amino acid sequence of SGSWLRDVWDWICTVLTDFK-
TWLQSKL (SEQ ID NO: 32) except that the exemplary AH 
peptides have one or more of the following amino acid sub-
stitutions relative to SEQ ID NO: 32: substitution of L at 
10 amino acidposition 16 byA orK; or substitutionofT at amino 
acid position 17 by A; or substitution of D at amino acid 
position 18 byA; or substitution of Fat amino acid position 19 
by A; or substitution of K at amino acid position 20 by A; or 
substitution of W at amino acid position 22 by A; or substi- 
15 tution of L at amino acid position 23 by K. 
Still further exemplary AH peptides include peptides hav-
ing an amino acid sequence of: 
20 (SEQ ID NO: 78) 
SGSX 1X2X3X4X5X6X7X8X9X lOXl 1X12X13X14X15X16X17X18 
X19X20QS KL , 
SWLWDVWDWVLHVLS (SEQ ID NO: 56)  25 wherein X l is A or F; X2 is A or K; X 3 is A or N; X4 is A or S; 
SWLYDIVNWVCTVLA (SEQ ID NO: 57)  X5 is D, I or S; X 6 is A or F; X 7 is A or S; X $ is A or F; X 9 is 
EorL;X 10 isAorS;X 11  is A, E or W; X12  is D or S; X13 is 
SWLRDIWDWVCTVLS (SEQ ID NO: 58)  A or K; X 14 is A, S or W; X 15 is A or S; X 16 is D or L; X17  is 
SWLRDVWDWICTVLTD (SEQ ID NO: 59)  30 A or L; X l ,, is A or W; X 19 is A or F; and X 20 is A or K. 
AH peptides can also be based on an amphipathic a.-helical 
SWLRDIWEWVLSILTD (SEQ ID NO: 60)  
amino acid sequence of HCV NSSB, which is exemplified by 
SWLRDIWEWVLSILTD (SEQ ID NO: 61)  the amino acid sequences: 
SWLRIIWDWVCSWSDF (SEQ ID NO: 62)  35 
SWLRTIWDWVCSVLAD (SEQ ID NO: 63)  QDVLKEVKAAASKVKANLLSVEE 	 (SEQ ID NO: 79) 
SWLHDIWDWVCIVLSD (SEQ ID NO: 64)  DVRCHARKAVAHINSVWKD 	 (SEQ ID NO: 80) 
SWLWDVWDWVLHVLSD (SEQ ID NO: 65)  AH peptides can also be based onanamphipathica-helical 40 
amino acid sequence of HCV NS413, which is exemplified by 
SWLYDIVNWVCTVLAD (SEQ ID NO: 66)  the amino acid sequence: 
SWLRDIWDWVCTVLSD (SEQ ID NO: 67)  
SWLRDVWDWICTVLTDF (SEQ ID NO: 68)  IEQGMMLAEQFKQKALGLLQTASRHAEV 	 (SEQ ID NO: 81) 
45 
SWLRDVWDWVCTILTDF (SEQ ID NO: 69)  Further AH peptides can also contain an amino acid 
sequence of the formula: 
SWLRDIWEWVLSILTDF (SEQ ID NO: 70)  
SWLRIIWDWVCSWSKFK (SEQ ID NO: 71)  50 	 X 1X2DVWDWI CTX3X4X5X6X7X8X9 , 	 (SEQ ID NO: 	 82) 
SWLRTIWDWVCSVLADF (SEQ ID NO: 72)  
with the proviso that when X 1 and X2 are present, X 1 is L and 
SWLHDIWDWVCIVLSDF (SEQ ID NO: 73)  X2 isR; whereinwhen X l and X2 are present, X3, X4, X5, X6, 
X7, X8 and X9 are optionally present, and when X 31  X41  X51  SWLWDVWDWVLHVLSDF (SEQ ID NO: 74 ) 55 X6 , X7 , X,, and X 9 are present, X 3 is V X4 is L, X5 is T, X 6 is 
SWLYDIVNWVCTVLADF (SEQ ID NO: 75)  D, X7  is F, X,, is K and X9 is T; and wherein when X 6 is 
present, X 31  X4 and X5 are all present, and X 6 is D, X3 is V, X4 
SWLRDIWDWVCTVLSDF (SEQ ID NO: 76)  is L, and X5 is T. 
A specific exemplary AH peptide having an NSSA amino 60 	 Exemplary AH peptides include those containing an amino 
acid sequence is: acid sequence of: 
SGSWLRDV_WDW I CTVLTDFKTWLQSKLDYK 	 (SEQ ID NO: 77) 	 LRDVWDWICTVLTDFKT; 	 (SEQ ID NO: 83) 
65 LRDVWDWICT; 	 (SEQ ID NO: 84) 
Notably, substitution of the hydrophobic residues underlined 
in the sequence immediately above with charged amino acids 
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-continued 
DVWDWICTVLTD; 	 (SEQ ID NO: 85) 
SWLRDVWDWIC; 	 (SEQ ID NO: 86) 
LCLAGRGLQEAEGLLLELLSEHHPLLDV 	 (SEQ ID NO: 87) 
or a fragment of 6 to 27 amino 
acids thereof; 
or 
ELGFQPGLKVAQHLAYPVPDVP 	 (SEQ ID NO: 88) 
or a fragment of 6 to 21 amino 
acids thereof. 
Other AH peptides include those described in WO 2002/ 
088731 and US 2004/0265792, which are incorporated 
herein by reference with respect to the disclosure of such 
peptides. 
AH peptides suitable for use in disruption of viral enve-
lopes, including variants (e.g., natural, recombinant, or syn-
thetic variants) of naturally-occurring AH peptides can be 
identified by, for example, modeling of the structure a 
selected peptide after the structure of an AH peptide having a 
naturally-occurring amino acid sequence of an amphipathic 
a-helix of an HCV NS protein, such as NS5A. Appropriate 
amphipathic and/or a-helical properties of such peptides can 
be assessed by a variety of different techniques, such as 
circular dichroism measurements. Activity in disruption of an 
enveloped virus can be assessed in an in vitro assay using a 
viral culture or using the lipid vesicle assay described in the 
Examples below. 
The amino acid sequences and three-dimensional structure 
of amphipathic a-helical peptides are well understood in the 
art. The ordinarily skilled artisan can readily generate vari-
ants of the AH peptide amino acid sequences described 
herein. For example, such substitutions can be made so that 
they are spaced at intervals along the predicted a-helix such 
that an a-helical structure with a hydrophobic face and a 
hydrophilic face is maintained. Thus AH peptide variants that 
retain activity in disruption of a viral envelope that have, for 
example, conservative amino acid substitutions relative to a 
naturally-occurring AH peptide amino acid sequence so as to 
result in replacement of amino acid residues of an AH peptide 
with residues that provide for similar charge, polarity, and 
retain the a-helical structure can be readily generated. 
It is appreciated that certain amino acid substitutions can 
result in peptides can disrupt the formation of the helix; 
however, the nature of these substitutions is already under-
stood by those of ordinary skill and can be avoided, or pur-
posefully used, as desired. Insertion of, for example, disrup-
tive proline residues, can be undesirable. Thus, it is well 
within ordinary skill to substitute one or more amino acids in 
these sequences to obtain AH peptides that retain the desired 
activity in disrupting viral envelopes. 
AH peptides can have residues linked by native amide 
bonds or by non-native bonds. Reference to "peptide" herein 
is meant to encompass both a polymer of amino acids linked 
by a native amide bonds or non-native amide bonds. 
It should be understood that as used throughout, and unless 
specifically indicated otherwise, the term "amino acid" is 
used herein in its broadest sense, and includes naturally 
occurring amino acids as well as non-naturally occurring 
amino acids, including amino acid analogs and derivatives. 
The latter includes molecules containing an amino acid moi-
ety. One skilled in the art will recognize, in view of this broad 
definition, that reference herein to an amino acid includes, for 
example, naturally occurring proteogenic L-amino acids; 
D-amino acids; chemically modified amino acids such as 
amino acid analogs and derivatives; naturally occurring non- 
proteogenic amino acids such as norleucine, p-alanine, orni-
thine, etc.; and chemically synthesized compounds having 
properties knowninthe artto be characteristic of amino acids. 
As used herein, the term "proteogenic" indicates that the 
5 amino acid can be incorporated into apeptide, polypeptide, or 
protein in a cell through a metabolic pathway. 
The incorporation of non-natural amino acids, including 
synthetic non-native amino acids, substituted amino acids, or 
one or more D-amino acids into the present AH peptides can 
io provide for, for example, increased stability in vitro or in vivo 
(e.g., D-amino acid-containing peptides as compared to 
L-amino acid-containing peptides). For example, AH pep-
tides incorporating 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more D-amino 
acids can be particularly useful when greater stability (e.g., in 
15 an in vivo setting) is desired or required. For example, 
D-amino acid-containing peptides can be provided that are 
resistant to peptidases and proteases, thereby providing 
improved bioavailability of the molecule, and prolonged life-
times in vivo and in vitro when such properties are desirable. 
20 Moreover, D-amino acid-containing peptides are not effi-
ciently processed for major histocompatibility complex class 
11-restricted presentation to T helper cells, and are therefore 
less likely to induce Immoral immune responses in the whole 
organism than purely L-amino acid-containing peptides. 
25 Selection of amino acid residues for use in an AH peptide, 
particularly one based on a naturally-occurring amphipathic, 
a-helical amino acid sequence (e.g., of NS5A), can take into 
consideration the hydropathic index of the amino acid present 
in the reference sequence and the hydropathic index of the 
3o amino acid residue proposed for substitution. The importance 
of the hydropathic amino acid index in conferring interactive 
biological action on a protein has been discussed by Kyte and 
Doolittle (1982, J. Mol. Biol., 157: 105-132). It is accepted 
that the relative hydropathic character of amino acids contrib- 
35 utes to the secondary structure of the resultant protein. This, 
in turn, affects the interaction of the protein with other mol-
ecules. 
Based on its amphipathic characteristics, which are influ-
enced by polarity and charge, each amino acid has been 
4o assigned a hydropathic index as follows: isoleucine (+4.5); 
valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteinel-
cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine 
(-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); 
tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate/ 
45 glutamine/aspartate/asparagine (-3.5); lysine (-3.9); and 
arginine (-4.5). 
Certain amino acids in a peptide, polypeptide, or protein 
can be substituted for other amino acids having a similar 
hydropathic index or score and produce a resultant peptide, 
50 etc., having similar biological activity, i.e., which still retains 
biological functionality in disrupting viral envelopes. In mak-
ing such changes, amino acids having hydropathic indices 
within ±2  can generally be substituted for one another. Exem-
plary suitable substitutions are those wherein the amino acids 
55 have hydropathic indices within ±1. Most preferred substitu-
tions are those wherein the amino acids have hydropathic 
indices within ±0.5. 
Like amino acids can also be substituted on the basis of 
hydrophilicity. U.S. Pat. No. 4,554,101, herein incorporated 
6o by reference, discloses that the greatest local average hydro- 
philicity of a protein, as governed by the hydrophilicity of its 
adjacent amino acids, correlates with a biological property of 
the protein. The following hydrophilicity values have been 
assigned to amino acids: arginine/lysine (+3.0); aspartate/ 
65 glutamate (+3.0±1); serine (t-0.3); asparagine/glutamine 
(+0.2); glycine (0); threonine (-0.4); proline (-0.5 1-1); ala- 
nine/histidine (-0.5); cysteine (-1.0); methionine (-1.3); 
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valine (-1.5); leucine/isoleucine (-1.8); tyrosine (-2.3); phe-
nylalanine (-2.5); and tryptophan (-3.4). Thus, one amino 
acid in a reference amino acid sequence can be substituted by 
another amino acid having a similar hydrophilicity score and 
still be expected to provide a peptide having similar biologi-
cal activity, e.g., retaining activity in disrupting viral enve-
lopes. In making such changes, amino acids having hydro-
pathic indices within 1-2 are substituted for one another, those 
within ±1  being of interest, and those within ±0.5 more usual. 
As outlined above, amino acid substitutions in the AH 
peptides can be based on the relative similarity of the amino 
acid side-chain substituents, for example, their hydrophobic-
ity, hydrophilicity, charge, size, etc. 
Exemplary substitutions that take various of the foregoing 
characteristics into consideration in order to produce conser-
vative amino acid changes resulting in AH peptides having 
changes that do not substantially affect activity in disrupting 
viral envelopes can be selected from other members of the 
class to which the naturally occurring amino acid belongs. 
Amino acids can be divided into the following four groups: 
(1) acidic amino acids; (2) basic amino acids; (3) neutral polar 
amino acids; and (4) neutral non-polar amino acids. Repre-
sentative amino acids within these various groups include, but 
are not limited to: (1) acidic (negatively charged) amino acids 
such as aspartic acid and glutamic acid; (2) basic (positively 
charged) amino acids such as arginine, histidine, and lysine; 
(3) neutral polar amino acids such as glycine, serine, threo-
nine, cysteine, cystine, tyrosine, asparagine, and glutamine; 
and (4) neutral non-polar amino acids such as alanine, leu-
cine, isoleucine, valine, proline, phenylalanine, tryptophan, 
and methionine. 
The AH peptides can be provided in the context of the 
nonstructural protein or fragment thereof or can be provided 
in the form of a fusion protein between an AH peptide and a 
heterologous polypeptide. For example, the AH peptide can 
be provided as a fusion protein that contains a detectable 
label, such as a fluorescent polypeptide (e.g., green fluores-
cent protein) or an immunodetectable label (e.g., FLAG, 
which can be exploited to facilitate isolation by immunoiso-
lation techniques). In other examples of AH peptide-contain-
ing fusion proteins, the heterologous polypeptide can be a 
virucidal peptide, a lipid binding protein (e.g., to facilitate 
clearance of lipids that may be by-products of disruption of 
viral envelopes, a polypeptide that enhances serum half-life 
(e.g., by increasing the size of the molecule, such as a PEGy-
lated polypeptide), an antibody or antigen binding fragment 
thereof; or a polypeptide that facilitates recombinant produc-
tion and/or isolation. Such AH peptide fusion proteins may 
include a spacer between the AH peptide amino acid 
sequence and the amino acid sequence of the heterologous 
polypeptide (e.g., to facilitate presentation of the amphipathic 
a-helix to viral envelopes). 
Methods of Making AH Peptides 
AH peptides can be produced according to any of a variety 
of methods known in the art, including recombinant and 
synthetic methods. AH peptides that are relatively short (e.g., 
50 residues or less) can generally be produced by suitable 
synthetic methods well known in the art. 
Since the genetic code and recombinant techniques for 
manipulating nucleic acid are known, and the amino acid 
sequences of AH peptides are exemplified above, the design 
and recombinant production of nucleic acids suitable for 
recombinant production of an AH peptide is well within the 
skill of an artisan. For example, standard recombinant DNA 
technology (Ausubel, et al, Short Protocols in Molecular 
Biology, 3rd ed., Wiley & Sons, 1995; Sambrook, et al., 
Molecular Cloning: A Laboratory Manual, Second Edition, 
18 
(1989) Cold Spring Harbor, N.Y) methods can be used to 
obtain (e.g., by isolating nucleic acid encoding an HCV 
polypeptide containing an AH peptide from a library of 
nucleic acids using any one or a combination of a variety of 
5 recombinant methods (e.g., PCR)). Where modification is 
desired, e.g., to subclone anAH peptide-containing sequence, 
to provide for conservative amino acid substitutions, etc.) site 
directed mutagenesis, PCR and other techniques can be used. 
Nucleic acids encoding an AH peptide may also be made by 
to chemical synthesis entirely from oligonucleotides. 
AH peptide-encoding constructs can be introduced into an 
appropriate host cell, where, when desired, the construct pro-
vides for a suitable operably linked promoter to provide for 
15 expression in the host cell (where such constructs are referred 
to as expression vectors). The constructs can be maintained as 
an episomal element or provide for host cell genomic inte-
gration. In this latter aspect, the AH peptide coding sequence 
may be In some embodiments, the constructs are simply to 
20 provide for production of additional construct DNA material, 
and thus in such embodiments need only provide for replica-
tion in the host cell. Constructs that facilitate genomic inte-
gration may provide for insertion of the AH peptide coding 
sequence adjacent a host cell promoter, or may provide for 
25 integration of a promoter-AH peptide expression cassette. 
Constructs may optionally contain one or more selection 
markers, e.g., tetracycline or neomycin, to permit detection of 
those cells transformed with the desired DNA sequences. 
Exemplary vectors include viral vectors, plasmids, cosmids, 
3o artificial chromosomes (human artificial chromosomes, bac-
terial artificial chromosomes, yeast artificial chromosomes, 
etc.), mini-chromosomes, and the like. Retroviral, adenoviral 
and adeno-associated viral vectors may be used. Expression 
constructs can further include 3' and 5' untranslated regions 
35 (UTRs) which may direct RNA stability, translational effi-
ciency; transcriptional terminators, and other elements that 
facilitate transcription and/or translation in a host cell. Con-
structs may also contain restriction sites, multiple cloning 
sites, primer binding sites, ligatable ends, recombination sites 
40 etc., usually in order to facilitate the construction of a nucleic 
acid encoding a polypeptide of interest. 
Promoters are selected according to the host cell in which 
expression is desired. Eukaryotic promoters can be any pro-
moter that is functional in a eukaryotic host cell, including 
45 viral promoters and promoters derived from eukaryotic 
genes. Exemplary eukaryotic promoters can include, but are 
not limited to, the following: the promoter of the mouse 
metallothionein I gene sequence (Hamer et al., J. Mol. Appl. 
Gen. 1:273-288, 1982); the TK promoter of Herpes virus 
50 (McKnight Cell 31:355-365, 1982); the SV40 early pro-
moter (Benoist et al., Nature (London) 290:304-310, 1981); 
the yeast gall gene sequence promoter (Johnston et al., Proc. 
Natl. Acad. Sci. (USA) 79:6971-6975, 1982); Silver et al., 
Proc. Natl. Acad. Sci. (USA) 81:5951-59SS,1984), the CMV 
55 promoter, the EF-1 promoter, Ecdysone-responsive 
promoter(s), tetracycline-responsive promoter, and the like. 
Viral promoters may be of particular interest as they are 
generally particularly strong promoters. In certain embodi-
ments, a promoter is used that is a promoter of the target 
60 pathogen. Promoters for use in the present invention are 
selected such that they are functional in the cell type (and/or 
animal) into which they are being introduced. In certain 
embodiments, the promoter is a CMV promoter. 
Host cells for production of AH peptide-encoding con- 
65 structs and/or production ofAH peptides can be selected from 
a variety of different host cells known in the art. Exemplary 
host cells include prokaryotic and eukaryotic host cells, 
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including bacterial, yeast, and mammalian host cells (e.g., 	 phils, eosinophils, etc.), or other host cells, thus avoiding or 
cultured mammalian cell lines). 	 reducing side effects (e.g., anemia, leucopenia, immunosup- 
Viruses Susceptible to Disruption by AH Peptides 	 pression, etc.). 
AH peptides effect viral envelope disruption, which serves 	 In specific embodiments of the methods disclosed herein, 
to inhibit viral infection, inhibit viral replication (e.g., due to 5 the disclosed AH peptides are used to disrupt enveloped 
reduced viruses to provide for infection), reduce viral load 	 viruses having an average particle diameter greater than about 
(e.g., by decreasing the relative amount of infective viral 	 80 mn in diameter and less than about 250 mn in diameter. For 
particles), reduce infectivity (e.g., as inthe context of a virally 	 example, in some embodiments the disclosedAH peptides are 
contaminated surface), and the like. 	 used to disrupt enveloped viruses having an average particle 
As discussed in the Examples, the efficacy in AH peptides io diameter greater than about 90 nm in diameter and less than 
in effecting viral envelope disruption is inversely propor- 	 about 250 mn in diameter, greater than about 100 mn in 
tional to enveloped viral particle size and directly propor- 	 diameter and less than about 250 mn in diameter, greater than 
tional to line tension. Stated differently, as the viral particle 	 about 110 mn in diameter and less than about 250 nm in 
size (e.g., as measured by particle diameter or radius) 	 diameter, greater than about 120 nm in diameter and less than 
increases, the efficiency of AH peptides disclosed herein to 15 about 250 nm in diameter, greater than about 130 nm in 
provide for disruption of the enveloped virus decreases. As 	 diameter and less than about 250 mn in diameter, greater than 
the line tension of an enveloped viral particle increases, the 	 about 140 mn in diameter and less than about 250 nm in 
efficiency of AH peptides in disrupting the enveloped viral 
	
diameter, greater than about 150 mn in diameter and less than 
particle increase. For example, as illustrated with the AH 	 about 250 mn in diameter, greater than about 160 mn in 
peptide exemplified in the Examples, while a population of 20 diameter and less than about 250 nm in diameter, greater than 
vesicles of about 58 mn average diameter were disrupted such 	 about 170 mn in diameter and less than about 250 nm in 
that no detectable intact vesicles were detected (100% dis- 	 diameter, greater than about 180 mn in diameter and less than 
ruption). In general particles having an average diameter of 	 about 250 mn in diameter, greater than about 190 mn in 
25 nm to 90 mn were disrupted such that no detectable intact 	 diameter and less than about 250 mn in diameter, greater than 
vesicles were detected (100% disruption). In contrast, when 25 about 200 mn in diameter and less than about 250 nm in 
an exemplary AH peptide was contacted with a population of 
	
diameter, greater than about 210 nm in diameter and less than 
vesicles of about 148 nm average diameter, about 75% were 	 about 250 nm in diameter, greater than about 220 nm in 
disrupted. It should be noted that while the efficiency of 
	
diameter and less than about 250 nm in diameter, greater than 
disruption will be decreased with increasing enveloped virus 	 about 230 nm in diameter and less than about 250 nm in 
particle size, this is not to say the AH peptides would not be 3o diameter, or greater than about 240 mn in diameter and less 
useful in "killing" such viruses. To the contrary, in the context 	 than about 250 nm in diameter. In one embodiment, the envel- 
of in vivo therapy, a reduction in viral load can serve to 	 oped virus to be disrupted using anAH peptide has an average 
provide for a level of viral infection that can be better handled 	 particle diameter of less than about 250 mn but does not have 
by the immune system of the host. In addition, AH peptide- 	 an average particle diameter of about 25 mn to about 80 nm in 
based therapies can be use in conjunction with other antiviral 35 diameter. 
therapies to provide for more complete viral inhibition. Simi- 	 Exemplary enveloped viruses that can be suitable to be 
larly in the context of extracorporeal use, AH peptides can be 	 disrupted using the AH peptides disclosed herein include 
used in conjunction with other virucidal agents to provide for 	 (from roughly larger to smaller particle diameter) poxvirus 
acceptable levels of infectious virus. 	 (about 170-200 mux300-450 mn average particle diameter), 
For example, in the context of AH peptides based on the 4o baculovirus (about 60 nmx300 nm size average particle diam- 
amphipathic a-helix of NS5A polypeptide, a population of 	 eter), paramyxoviruses (about 150-300 mn average particle 
vesicles an average diameter of about 50 mn were disrupted 
	
diameter), arenaviruses (about 50-300 nm average particle 
so that no detectable intact vesicle remained, with vesicles 	 diameter), herpesviruses (about 150-200 nm average particle 
having an average diameter of 25 mn to 90 mn also being 	 diameter, e.g., HSV (e.g., HSVI, HSV2), CMV, EBV, etc.), 
"completely" disrupted while a population of vesicles having 45 orthomyxoviruses (about 90-120 nm average particle diam- 
an average diameter of about 148 nm were about 75% dis- 	 eter), bunya viruses (about 90-120 mn average particle diam- 
rupted. The methods thus contemplate use of AH peptides to 	 eter), coronaviruses (about 80-160 nm average particle diam- 
provide for disruption of about 20%, 25%, 30%, 35%, 40%, 	 eter), retroviruses (about 80-100 mn average particle 
45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 	 diameter; e.g., HIV), togaviruses (about 60-70 mn average 
95%, or 99% or greater up to 100% of enveloped virions in a 50 particle diameter), and flaviviruses (about 40-50 nm average 
population of enveloped virions. It is noted that even at low 	 particle diameter), and hepadnaviruses (about 42 nm average 
levels of disruption, the AH peptides can be useful when used 	 particle diameter, e.g., HBV). In one embodiment, the virus to 
in conjunction with a second antiviral agent (e.g., a second 	 be disrupted using an AH peptide is other than an HCV virus. 
disinfectant or second antiviral therapeutic). 	 Susceptibility of enveloped viruses to disruption by AH 
Thus the present disclosure contemplates methods in 55 peptides can also be assessed by line tension. Enveloped viral 
which the AH peptides disclosed herein are used to disrupt 	 particles having a line tension of greater than from about 
enveloped viruses having an average particle diameter of less 	 10-12 Newtons (N) to about 10-14 Newtons have increased 
than 250 mu, 200 nm, or 150 nm, with enveloped viruses 	 susceptibility to disruption by AH peptides, while enveloped 
having an average particle diameter of less than 110 nm, 100 	 viral particles having a line tension of less than these values 
mu, 95 nm, 90 mu, 85 nm, 80 nm, 75 mu, 70 nm, 65 mu, 60 6o are generally less susceptible to disruption. 
mu, 55 nm, 50 nm, 45 nm, or 40 nm in diameter. Notably, the 	 Diseases Susceptible to Treatment Using AH Peptides 
size of particles susceptible to disruption by AH peptides 	 Diseases susceptible to treatment using one or more of the 
disclosed herein is much smaller than the size of, for example, 	 AH peptides disclosed herein include, but are not limited to, 
human red blood cells which are on the order of microns in 	 diseases caused by infection of a host with one or more of the 
diameter. Thus the AH peptides may provide for antiviral 65 above viruses. For example, the peptides disclosed herein 
activity without disruption of human red blood cells, human 	 may be used to treat disease caused by one or more of the 
immune cells (e.g., T cells, B cells, macrophages, neutro- 	 following viruses: poxvirus, baculovirus, paramyxoviruses, 
US 8,728,793 B2 
21 
	
22 
arenaviruses, herpesviruses (e.g., HSV (e.g., HSV1, HSV2), 	 about 300 mM, about 350 mM, about 400 mM, about 450 
CMV, EBV, etc.), orthomyxoviruses, bunya viruses, coro- 	 mM, about 500 mM, 550 mM, or about 600 mM is achieved. 
naviruses, retroviruses (e.g., HIV), togaviruses, flaviviruses 	 AH peptide formulations include those that provide for a 
and hepadnaviruses. In one embodiment, the disease to be 	 microenvironment at the site of delivery that reflects one or 
treated using an AH peptide is other than one caused by an 5 more of these formulation parameters. It should be under- 
HCV virus. 	 stood that benefit provided by the adjustment of one or more 
Exemplary diseases that may be caused by one or more of 	 of the above parameters may depend on one or more of the 
the above viruses and which may be susceptible to treatment 	 other parameters. For example, as indicated in the Examples 
using one or more of theAH peptides disclosed herein include 	 the benefit provided by adjusting pH or osmolality may 
small pox, mumps, measles, bronchiolitis, pneumonia, respi-  io depend on the concentration of AH peptide used in the for-
ratory tract disease, croup, bronchitis, phocine distemper 	 mulation. 
virus, Newcastle disease, hemorrhagic fevers (e.g., Bolivian, 	 Formulations for Use in as General Virucidal Disinfectant 
Argentine, Brazilian, Venezuelan, and Lassa hemorrhagic 	 Composition 
fevers), mucocutaneous infection as a result of infection with 	 AH peptides can be provided in formulations suitable for 
herpes virus, gingivostomatitis, herpes labialis, genital her-  15 use as a disinfectant. Because such formulations are useful in 
pes, herpes simplex keratitis, neonatal herpes simplex, 	 contexts that do not involve administration to a subject, such 
encephalitis resulting from infection with herpes virus, influ- 	 antiviral formulations can contain a carrier which is other 
enza, Rift Valley Fever, Sandfly Fever, California Encephali- 	 than a pharmaceutically acceptable carrier suitable for human 
tis, Oropouche Fever, Crimean-Congo Hemorrhagic Fever, 	 administration. Where the formulations are used to treat a 
Sin Nombre Virus/Four Corner's Disease, Hemorrhagic 20 biological fluid (e.g., blood) which is then to be administered 
Fever with Renal Syndrome, severe acute respiratory syn- 	 to a subject, theAH peptides shouldbe formulated so thatthey 
drome (SARS), enzootic bovine leukosis, equine infectious 	 contain a pharmaceutically acceptable carrier or have levels 
anaemia and caprine arthritis-encephalitis, Acquired Immune 	 of otherwise non-pharmaceutically acceptable components 
Deficiency Syndrome (AIDS), Chikungunya, Eastern and 	 that are sufficiently diluted in the biological fluid or tissue to 
Western Equine Encephalitis, Venezuelan Equine Encephali-  25 be treated to that the are non-toxic to the subject receiving the 
tis, St. Louis Encephalitis, West Nile Encephalitis, Yellow 	 biological fluid or tissue. 
fever, Dengue fever and Dengue Hemorrhagic fever, and liver 	 Suitable diluents for suchAH peptide formulations include 
infection caused by hepadnavirus infection. 	 any of a number of compounds used in the preparation of 
AH Peptide Formulations 	 isotonic solutions. Exemplary solutes include but are not 
AH peptides will generally be formulated in accordance 30 limited to sugars such as dextrose and glucose, polysaccha- 
with the use to which the AH peptides will be applied. For- 	 rides such as dextran, albumin, and salts of alkali earth metals 
mulations generally contain AH peptides at a concentration 	 including sodium chloride, potassium chloride, and potas- 
suitable for the purpose to which the formulation is to be 	 sium bromide. Exemplary combinations of solutes known for 
applied (e.g., disinfectant, therapy). 	 their utility in storing peptides can also be suitable and 
The AH peptides, or AH peptide compositions, may com-  35 include, without limitation, such combinations as citrate-
prise, consist essentially of, or consist of the peptide 	 phosphate-dextrose, 	 citrate-phosphate-dextrose-adenine, 
sequences, or AH peptides, disclosed herein. The phrase 	 and saline-mannitol-dextrose-adenine. 
"consists essentially of or consisting essentially of or the 	 Diluents having utility in the practice of the present meth- 
like, when applied to AH peptides refers to peptide sequences 	 ods for their isotonic characteristics can be combined. Com- 
like those disclosed herein, but which contain additional 4o bining diluents is particularly suitable when disinfecting red 
amino acids (or analogs or derivatives thereof as discussed 	 blood cells because commercial collective units of red blood 
above). Such additional amino acids, etc., however, do not 	 cells are frequently stored in isotonic solutions containing 
materially affect the basic and novel characteristic(s) of these 	 anti-coagulant, such as ACID (acid-citrate-dextrose), CPD 
peptides in disrupting viral envelopes. 	 (citrate-phosphate-dextrose), CPD-A (CPD-adenine). Thus, 
AH peptide formulations can contain 2, 3, 4, 5, or more 45 when disinfecting collective units of red blood cells stored in 
different AH peptides, and may further contain components 	 isotonic solutions of anti-coagulant, the disinfectant compo- 
that provide for stability of the peptide in solution. 	 sition may be prepared in a different isotonic diluent, e.g., 
AH peptide formulations can be provided so as to facilitate 	 normal saline, and combined with the anti-coagulant solu- 
efficient lysis of enveloped virus by the AH peptide. One or 	 tion. 
more AH peptide formulation parameters that can be modu-  50 As noted above, theAH peptides can be formulated so as to 
lated so as to provide for enhancedAH peptide-mediated lysis 	 facilitate efficient lysis of enveloped virus by theAH peptide. 
include, but are not necessarily limited to, concentration of 
	
In the context of use of AH peptide formulations as general 
AH peptide, pH, and osmolality. For example, an AH peptide 	 virucidal disinfectants, AH peptide formulation parameters 
formulation having a pH of 7.5 or less may be utilized, e.g., a 	 can be modulated so as to provide an AH peptide formulation 
pH of about 7.0, about 6.5, about 6.0, about 5.5, about 5.0, 55 having, for example, a pH of 7.5 or less, e.g., a pH of about 
about 4.5, or about 4.0. The concentration of the AH peptide 	 7.0, about 6.5, about 6.0, about 5.5, about 5.0, about 4.5, or 
in the formulation can also be adjusted to facilitate efficient 	 about 4.0. The concentration of the AH peptide in the formu- 
lysis of enveloped virus. For example, concentrations of 
	
lation can also be adjusted to facilitate efficient lysis of envel- 
about 1 µM, 2 µM, 3 µM, 4 µM, 5 µM, 6 µM, 7 µM, 8 µM, 9 	 oped virus. For example, concentrations of about 1 µM, 2 µM, 
µM, 10 µM, 11 µM, 12 µM, 13 µM, 14 µM, or 15 µM can be 60 3 µM, 4 µM, 5 µM, 6 µM, 7 µM, 8 µM, 9 µM, 10 µM, 11 µM, 
utilized in an AH peptide formulation. The osmolality of the 	 12 µM, 13 µM, 14 µM, or 15 µM can be utilized in an AH 
formulation can also be adjusted so as to facilitate efficient 	 peptide formulation. The osmolality of the formulation can 
lysis of enveloped virus by the AH peptide. For example, the 	 also be adjusted so as to facilitate efficient lysis of enveloped 
concentration of one or more salts in an AH peptide formu- 	 virus by the AH peptide. For example, the concentration of 
lation can be adjusted such that an osmotic pressure equiva-  65 one or more salts in an AH peptide formulation can be 
lent to that of a solution with a NaCl concentration of about 	 adjusted such that an osmotic pressure equivalent to that of a 
100 mM, about 150 mM, about 200 mM, about 250 mM, 	 solution with a NaCl concentration of about 100 mM, about 
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150 mM, about 200 mM, about 250 mM, about 300 mM, 
about 350 mM, about 400 mM, about 450 mM, about 500 
mM, 550 mM, or about 600 mM is achieved. AH peptide 
formulations include those that provide for a microenviron-
ment at the site of delivery that reflects one or more of these 
formulation parameters. It should be understood that benefit 
provided by the adjustment of one or more of the above 
parameters may depend on one or more of the other param-
eters. For example, as indicated in the Examples the benefit 
provided by adjusting pH or osmolality may depend on the 
concentration of AH peptide used in the formulation. 
Formulations for Antiviral Therapy 
AH peptides can be formulated for therapy in humans or 
non-humans in accordance with known methods compatible 
with peptide drugs, and which maintain the activity of theAH 
peptide in disrupting viral envelopes of enveloped viruses 
having a diameter of less than about 250 mu. 
As noted above, theAH peptides can be formulated so as to 
facilitate efficient lysis of enveloped virus by theAH peptide. 
In the context of use of AH peptide formulations in antiviral 
therapy, the AH peptide formulation parameters should pro-
vide for a formulation that remains suitable for administration 
to a host according to the desired route of administration. For 
example, a topical AH peptide formulation can be modified 
with respect to pH (e.g., a pH below pH 7.5). AH peptide 
formulation parameters that can be modulated so as to pro-
vide an AH peptide formulation suitable for use in a therapy 
include, but are not necessarily limited to concentration of 
AH peptide, pH, and osmolality. For example, an AH peptide 
formulation having a pH of 7.5 or less may be utilized, e.g., a 
pH of about 7.0, about 6.5, about 6.0, about 5.5, about 5.0, 
about 4.5, or about 4.0. The concentration of the AH peptide 
in the formulation can also be adjusted to facilitate efficient 
lysis of enveloped virus. For example, concentrations of 
about 1 µM, 2 µM, 3 µM, 4 µM, 5 µM, 6 µM, 7 µM, 8 µM, 9 
µM, 10 µM, 11 µM, 12 µM, 13 µM, 14 µM, or 15 µM can be 
utilized in an AH peptide formulation. The osmolality of the 
formulation can also be adjusted so as to facilitate efficient 
lysis of enveloped virus by the AH peptide. For example, the 
concentration of one or more salts in an AH peptide formu-
lation can be adjusted such that an osmotic pressure equiva-
lent to that of a solution with a NaCl concentration of about 
100 mM, about 150 mM, about 200 mM, about 250 mM, 
about 300 mM, about 350 mM, about 400 mM, about 450 
mM, about 500 mM, 550 mM, or about 600 mM is achieved. 
AH peptide formulations include those that provide for a 
microenvironment at the site of delivery that reflects one or 
more of these formulation parameters. It should be under-
stood that benefit provided by the adjustment of one or more 
of the above parameters may depend on one or more of the 
other parameters. For example, as indicated in the Examples 
the benefit provided by adjusting pH or osmolality may 
depend on the concentration of AH peptide used in the for-
mulation. 
AH peptides, e.g., in the form of a pharmaceutically 
acceptable salt, can be formulated for oral, topical or 
parenteral administration for use in the methods disclosed 
herein. In certain embodiments, e.g., where an AH peptide is 
administered as a liquid injectable (such as in those embodi-
ments where they are administered intravenously or directly 
into a tissue), an AH peptide formulation is provided as a 
ready-to-use dosage form, or as a reconstitutable storage-
stable powder or liquid composed of pharmaceutically 
acceptable carriers and excipients. 
Methods for producing and formulating AH peptides suit-
able for administration to a subject (e.g., a human subject) are 
well known in the art. For example, AH peptides can be 
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provided in a pharmaceutical composition comprising an 
effective amount of an AH peptide and a pharmaceutical 
excipients (e.g., saline). The pharmaceutical composition 
may optionally include other additives (e.g., buffers, stabiliz- 
5 ers, preservatives, and the like). An effective amount of AH 
peptide is generally an amount effective to provide for 
enhancing an antiviral effect in a subject for a desired period. 
A therapeutic goal (e.g., reduction in viral load) can be 
accomplished by single or multiple doses under varying dos- 
lo ing regimen. 
By way of illustration, theAH peptide compositions can be 
admixed with conventional pharmaceutically acceptable car-
riers and excipients (i.e., vehicles) and used in the form of 
15 aqueous solutions, tablets, capsules, elixirs, suspensions, syr-
ups, wafers, patches and the like. Such pharmaceutical com-
positions contain, in certain embodiments, from about 0.1 to 
about 90% by weight of the active compound, and more 
generally from about 1 to about 30% by weight of the active 
20 compound. The pharmaceutical compositions may contain 
common carriers and excipients, such as corn starch or gela-
tin, lactose, dextrose, sucrose, microcrystalline cellulose, 
kaolin, mannitol, dicalcium phosphate, sodium chloride, and 
alginic acid. Disintegrators commonly used in pharmaceuti- 
25 cal formulations include croscarmellose, microcrystalline 
cellulose, corn starch, sodium starch glycolate and alginic 
acid. 
A liquid composition will generally consist of a suspension 
or solution of the compound or pharmaceutically acceptable 
30 salt in a suitable liquid carrier(s), for example, ethanol, glyc-
erine, sorbitol, non-aqueous solvent such as polyethylene 
glycol, oils or water, with a suspending agent, preservative, 
surfactant, wetting agent, flavoring or coloring agent. Alter-
natively, a liquid formulation can be prepared from a recon- 
35 stitutable powder. 
For example, a powder containing active compound, sus-
pending agent, sucrose and a sweetener can be reconstituted 
with water to form a suspension; and a syrup can be prepared 
from a powder containing active ingredient, sucrose and a 
40 sweetener. A composition in the form of a tablet can be 
prepared using any suitable pharmaceutical carrier(s) rou-
tinely used for preparing solid compositions. Examples of 
such carriers include magnesium stearate, starch, lactose, 
sucrose, microcrystalline cellulose and binders, for example, 
45 polyvinylpyrrolidone. The tablet can also be provided with a 
color film coating, or color included as part of the carrier(s). 
In addition, active compound can be formulated in a con-
trolled release dosage form as a tablet comprising a hydro-
philic or hydrophobic matrix. 
50 A composition in the form of a capsule can be prepared 
using routine encapsulation procedures, for example, by 
incorporation of active compound and excipients into a hard 
gelatin capsule. Alternatively, a semi-solid matrix of active 
compound and high molecular weight polyethylene glycol 
55 can be prepared and filled into a hard gelatin capsule; or a 
solution of active compound in polyethylene glycol or a sus-
pension in edible oil, for example, liquid paraffin or fraction-
ated coconut oil can be prepared and filled into a soft gelatin 
capsule. 
60 	 Tablet binders that can be included are acacia, methylcel- 
lulose, sodium carboxymethylcellulose, poly-vinylpyrroli-
done (Povidone), hydroxypropyl methylcellulose, sucrose, 
starch and ethylcellulo se. Lubricants that can be used include 
magnesium stearate or other metallic stearates, stearic acid, 
65 silicone fluid, talc, waxes, oils and colloidal silica. Flavoring 
agents such as peppermint, oil of wintergreen, cherry flavor-
ing or the like can also be used. Additionally, it may be 
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desirable to add a coloring agent to make the dosage form 
more attractive in appearance or to help identify the product. 
AH peptides and their pharmaceutically acceptable salts 
that are active when given parenterally can be formulated for 
intramuscular, intrathecal, or intravenous administration. 
A typical composition for intramuscular or intrathecal 
administration will be of a suspension or solution of active 
ingredient in an oil, for example, arachis oil or sesame oil. A 
typical composition for intravenous or intrathecal adminis-
tration will be a sterile isotonic aqueous solution containing, 
for example, active ingredient and dextrose or sodium chlo-
ride, or a mixture of dextrose and sodium chloride. Other 
examples are lactated Ringer's injection, lactated Ringer's 
plus dextrose injection, Normosol-M and dextrose, Isolyte E, 
acylated Ringer's injection, and the like. Optionally, a co-
solvent, for example, polyethylene glycol, a chelating agent, 
for example, ethylenediamine tetracetic acid, and an anti-
oxidant, for example, sodium metabisulphite may be 
included in the formulation. Alternatively, the solution can be 
freeze dried and then reconstituted with a suitable solvent just 
prior to administration. 
AH peptides and their pharmaceutically acceptable salts 
which are active on rectal administration can be formulated as 
suppositories. A typical suppository formulation will gener-
ally consist of active ingredient with a binding and/or lubri-
cating agent such as a gelatin or cocoa butter or other low 
melting vegetable or synthetic wax or fat. 
AH peptides and their pharmaceutically acceptable salts 
which are active on topical administration can be formulated 
as transdermal compositions or transdermal delivery devices 
("patches"). Such compositions include, for example, a back-
ing, active compound reservoir, a control membrane, liner 
and contact adhesive. Such transdermal patches may be used 
to provide continuous or discontinuous infusion of AH pep-
tides in controlled amounts. The construction and use of 
transdermal patches for the delivery of pharmaceutical agents 
is well known in the art. See, e.g., U.S. Pat. No. 5,023,252, 
herein incorporated by reference in its entirety. Such patches 
may be constructed for continuous, pulsatile, or on demand 
delivery of pharmaceutical agents. 
In certain embodiments of interest, the AH peptide com-
position is administered as a single pharmaceutical formula-
tion. It also may be administered with an effective amount of 
another agent that includes other suitable compounds and 
carriers, and also may be used in combination with other 
active agents. The present disclosure thus provide pharma-
ceutically acceptable AH peptide compositions comprising 
pharmaceutically acceptable excipients. The pharmaceuti-
cally acceptable excipients include, for example, any suitable 
vehicles, adjuvants, carriers or diluents, and are readily avail-
able to the public. The pharmaceutical compositions may 
further contain other active agents as are well known in the 
art. 
One skilled in the art will appreciate that a variety of 
suitable methods of administering a formulation of AH pep-
tide to a subject or host, e.g., patient, in need thereof, are 
available, and, although more than one route can be used to 
administer a particular formulation, a particular route can 
provide a more immediate and more effective reaction than 
another route. Pharmaceutically acceptable excipients are 
also well-known to those who are skilled in the art, and are 
readily available. The choice of excipient will be determined 
in part by the particular compound, as well as by the particular 
method used to administer the composition. Accordingly, 
there is a wide variety of suitable formulations of the phar- 
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maceutical composition ofAH peptides. The following meth-
ods and excipients are merely exemplary and are in no way 
limiting. 
Formulations suitable for oral administration can consist of 
5 (a) liquid solutions, such as an effective amount of the com-
pound dissolved in diluents, such as water, saline, or orange 
juice; (b) capsules, sachets or tablets, each containing a pre-
determined amount of the active ingredient, as solids or gran-
ules; (c) suspensions in an appropriate liquid; and (d) suitable 
io emulsions. Tablet forms can include one or more of lactose, 
mannitol, corn starch, potato starch, microcrystalline cellu-
lose, acacia, gelatin, colloidal silicon dioxide, croscarmellose 
sodium, talc, magnesium stearate, stearic acid, and other 
excipients, colorants, diluents, buffering agents, moistening 
15 agents, preservatives, flavoring agents, and pharmacologi-
cally compatible excipients. Lozenge forms can comprise the 
active ingredient in a flavor, usually sucrose and acacia or 
tragacanth, as well as pastilles comprising the active ingredi-
ent in an inert base, such as gelatin and glycerin, or sucrose 
20 and acacia, emulsions, gels, and the like containing, in addi-
tion to the active ingredient, such excipients as are known in 
the art. 
AH peptide formulations can be made into aerosol formu-
lations to be administered via inhalation. These aerosol for- 
25 mulations can be placed into pressurized acceptable propel-
lants, such as dichlorodifluoromethane, propane, nitrogen, 
and the like. They may also be formulated as pharmaceuticals 
for non-pressured preparations such as for use in a nebulizer 
or an atomizer. 
30 	 Formulations suitable for parenteral administration 
include aqueous and non-aqueous, isotonic sterile injection 
solutions, which can contain anti-oxidants, buffers, bacteri-
ostats, and solutes that render the formulation isotonic with 
the blood of the intended recipient, and aqueous and non- 
35 aqueous sterile suspensions that can include suspending 
agents, solubilizers, thickening agents, stabilizers, and pre-
servatives. The formulations can be presented in unit-dose or 
multi-dose sealed containers, such as ampules and vials, and 
can be stored in a freeze-dried (lyophilized) condition requir- 
40 ing only the addition of the sterile liquid excipient, for 
example, water, for injections, immediately prior to use. 
Extemporaneous injection solutions and suspensions can be 
prepared from sterile powders, granules, and tablets of the 
kind previously described. 
45 	 Formulations suitable for topical administration may be 
presented as creams, gels, pastes, or foams, containing, in 
addition to the active ingredient, such carriers as are known in 
the art to be appropriate. 
Suppository formulations are also provided by mixing with 
5o a variety of bases such as emulsifying bases or water-soluble 
bases. Formulations suitable for vaginal administration may 
be presented as pessaries, tampons, creams, gels, pastes, 
foams. Unit dosage forms for oral or rectal administration 
such as syrups, elixirs, and suspensions may be provided 
55 wherein each dosage unit, for example, teaspoonful, table-
spoonful, tablet or suppository, contains a predetermined 
amount of the composition containing one or more inhibitors. 
Similarly, unit dosage forms for injection or intravenous 
administration may comprise the inhibitor(s) in a composi- 
60 tion as a solution in sterile water, normal saline or another 
pharmaceutically acceptable carrier. 
The term "unit dosage form," as used herein, refers to 
physically discrete units suitable as unitary dosages for 
human and animal subjects, each unit containing a predeter- 
65 mined quantity of AH peptide calculated in an amount suffi- 
cient to produce the desired effect in association with a phar- 
maceutically acceptable diluent, carrier or vehicle. The 
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specifications for the novel unit dosage forms of AH peptide 
depend on the particular compound employed and the effect 
to be achieved, and the pharmacodynamics associated with 
each compound in the host. Those of skill in the art will 
readily appreciate that dose levels can vary as a function of the 
specific compound, the nature of the delivery vehicle, and the 
like. Suitable dosages for a given compound are readily deter-
minable by those of skill in the art by a variety of means. 
Optionally, the pharmaceutical composition may contain 
other pharmaceutically acceptable components, such a buff-
ers, surfactants, antioxidants, viscosity modifying agents, 
preservatives and the like. Each of these components is well-
known in the art. See, e.g., U.S. Pat. No. 5,985,310, the 
disclosure of which is herein incorporated by reference. 
Other components suitable for use in the AH peptide for-
mulations can be found in Remington's Pharmaceutical Sci-
ences, Mack Pub. Co., 18th edition (June 1995). In an 
embodiment, the aqueous cyclodextrin solution further com-
prise dextrose, e.g., about 5% dextrose. 
Methods of Use 
TheAH peptides canbe used in a variety of settings both in 
vivo and in vitro to provide for disruption of enveloped 
viruses. 
The terms "an effective amount" (or, in the context of a 
therapy, a "pharmaceutically effective amount") of an AH 
peptide generally refers to an amount of AH peptide, or com-
binations of AH peptides, effective to facilitate disruption of 
viral envelopes to provide for a reducing in infectious viral 
particles, e.g., to provide for disinfecting a surface; reducing 
viral load in an infected subject; reducing or ameliorating 
conditions, symptoms, or disorders associated with viral 
infection in an affected subject; and the like. 
Effective amounts of AH peptides, suitable delivery 
vehicles, and protocols can be determined by conventional 
means. For example, in the context of therapy a medical 
practitioner can commence treatment with a low dose of one 
or more AH peptides in a subject or patient in need thereof, 
and then increase the dosage, or systematically vary the dos-
age regimen, monitor the effects thereof on the patient or 
subject, and adjust the dosage or treatment regimen to maxi-
mize the desired therapeutic effect. Further discussion of 
optimization of dosage and treatment regimens can be found 
in Benet et al., in Goodman & Gilman's The Pharmacological 
Basis of Therapeutics, Ninth Edition, Hardman et al., Eds., 
McGraw-Hill, New York, (1996), Chapter 1, pp. 3-27, and L. 
A. Bauer, in Phan nacotherapy, A Pathophysiologic 
Approach, Fourth Edition, DiPiro et al., Eds., Appleton & 
Lange, Stamford, Conn., (1999), Chapter 3, pp. 21-43, and 
the references cited therein, to which the reader is referred. 
The dosage levels and mode of administration will be 
dependent on a variety of factors such as the AH peptide(s) 
used, the context of use (e.g., the surface to be treated, the 
patient to be treated), and the like. Optimization of modes of 
administration, dosage levels, and adjustment of protocols, 
including monitoring systems to assess effectiveness are rou-
tine matters well within ordinary skill. 
In addition, in certain embodiments, the AH peptides are 
delivered under conditions that enhance activity of the AH 
peptide in facilitating lysis of enveloped virus. For example, 
use of AH peptides can be under a temperature condition 
which enhances activity of the AH peptide in mediating lysis. 
For example, contacting the AH peptide with the material to 
be treated under a temperature 20° C. or greater, 25° C. or 
greater, or 30° C. or greater can provide for enhanced effi-
ciency of viral lysis, e.g., so as to mediate lysis of at least 70%, 
at least 75%, at least 80%, at least 85% at least 90% or at least 
95% of viral particles in a starting population. The tempera- 
ture will generally be selected so as to be compatible with the 
use intended and/or the material to be treated (e.g., biological 
material versus non-biological material). 
The pH conditions under which theAH peptide is delivered 
5 can also me modulated so as to enhance activity of the AH 
peptide in facilitating lysis of enveloped virus. For example a 
pH of 7.5 or less may be utilized, e.g., a pH of about 7.0, about 
6.5, about 6.0, about 5.5, about 5.0, about 4.5, or about 4.0. 
The concentration of one or more AH peptides can also be 
l0 
adjusted to facilitate efficient lysis of enveloped virus. For 
example, concentrations of about 1 µM, 2 µM, 3 µM, 4 µM, 5 
µM, 6 µM, 7 µM, 8 µM, 9 µM, 10 µM, 11 µM, 12 µM, 13 µM, 
14 µM, or 15 µM can be utilized. In some embodiments, an 
15 increase in the concentration of the AH peptide provides for 
an enhanced activity of the AH peptide in facilitating lysis of 
enveloped virus. 
Where, theAH peptide is used in solution, the o smolality of 
the solution can be adjusted so as to facilitate efficient lysis of 
20 enveloped virus by the AH peptide. For example, the concen-
tration of one or more salts in the solution can be adjusted 
such that an osmotic pressure equivalent to that of a solution 
with a NaCl concentration of about 100 mM, about 150 mM, 
about 200 mM, about 250 mM, about 300 mM, about 350 
25 mM, about 400 mM, about 450 mM, about 500 mM, 550 mM, 
or about 600 mM is achieved. 
Suitable conditions for use with the application of an AH 
peptide include those that provide for a microenvironment at 
the site of application that reflects one or more of these for- 
30 mulation parameters. It should be understood that benefit 
provided by the adjustment of one or more of the above 
parameters may depend on one or more of the other param-
eters. For example, as indicated in the Examples the benefit 
provided by adjusting pH or osmolality may depend on the 
35 concentration of AH peptide used in the formulation. 
Exemplary methods are described below in further detail. 
Disinfection and/or Sterilization Uses 
The disclosure contemplates the useAH peptides in a vari-
ety of disinfection and/or sterilization methods. 
40 For example, AH peptides find use in methods of reducing 
viral contamination from a biological material. `Biological 
materials" include, but are not limited to, biological fluids 
(e.g., blood), biological solutions comprising blood, a blood 
component, and cell culture or a component of a cell culture 
45 (with the proviso the enveloped virus to be treated with AH 
peptide is other than HCV). 
Exemplary biological fluids include but are not limited to: 
whole blood; anti-coagulated whole blood (AWB); packed 
red cells obtained from AWB; platelet-rich plasma (PRP) 
50 obtained from AWB; platelet concentrate (PC) obtained from 
AWB or PRP; plasma obtained from AWB or PRP; red cells 
separated from plasma and resuspended in physiological 
fluid; and platelets separated from plasma and resuspended in 
physiological fluid. Blood product or biological fluid also 
55 includes any treated or untreated fluid associated with living 
organisms, particularly blood, including whole blood, warm 
orcoldblood, and stored or fresh blood; treatedblood, suchas 
blood diluted with a physiological solution, including but not 
limited to saline, nutrient, and/or anticoagulant solutions; one 
60 or more blood components, such as platelet concentrate (PC), 
platelet-rich plasma (PRP, platelet-free plasma, platelet-poor 
plasma, plasma, or packed red cells (PRC); analogous blood 
products derived from blood or a blood component or derived 
from bone marrow. The biological fluid may include leuco- 
65 cytes, or may be treated to remove leucocytes. Each of these 
blood products or biological fluids may be processed in the 
manner described herein. 
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In general, the method comprises contacting the biological 	 modified amino acid which in turn can be attached to a sub- 
material with anAH peptide in an amount effective to provide 	 strate surface (e.g., a resin, bead, etc.). In some embodiments, 
for disruption of enveloped viral particles that may be present 	 the substrate is other than a cell culture dish or research 
in the biological solution, where the AH peptides are present 	 reagent vial. 
in an amount sufficient to disrupt enveloped virus in the blood 5 	 Flowable material which may contain an enveloped virus 
which enveloped viruses are less than about 250 mn in diam- 	 having a diameter of less than about 250 mn (e.g., is suspected 
eter. 	 or known to contain such a virus) is brought into contact with 
In one embodiment, theAH peptides are used in methods to 	 the immobilized AH peptides, e.g., by flowing the material 
provide for disinfection of whole blood and/or blood prod- 	 over the surface and/or incubating the material with the AH 
ucts. AH peptides can be used in the disinfection and/or io peptide-containing surface. 
sterilization of a variety of blood products such as whole 	 In some embodiments, substrates having immobilized AH 
blood for transfusion, blood cells, blood plasma and blood 	 peptides are adapted for use in a biological fluid processing 
plasma proteins. Since whole blood is rarely used, the present 	 assembly. In general such substrates are constructed of any 
methods are more particularly directed to processes for dis- 	 material compatible with a biological fluid, such as whole 
infecting compositions containing red blood cells and/or 15 blood or a blood component, and where used in connection 
blood plasma. In certain embodiments, a method for treating 	 with a biological fluid processing assembly are further 
blood and/or blood products involves contacting the blood 	 adapted to withstand centrifugation. Exemplary containers 
and/or blood products with a composition comprising one or 	 which may be adapted for use as AH peptide-immobilization 
more AH peptides, where the AH peptides are present in an 	 substrates include blood collection and satellite bags (e.g., 
amount sufficient to disrupt enveloped virus in the blood 20 made from plasticized polyvinyl chloride, e.g. PVC plasti- 
which enveloped viruses are less than about 250 mn in diam- 	 cized with dioctylphthalate, diethylhexylphthalate, or trio- 
eter. The method may further include removing the AH pep- 	 ctyltrimellitate). The bags may also be formed from polyole- 
tides from the blood or blood product. 	 fin, polyurethane, polyester, and polycarbonate. 
In another embodiment, biological materials, especially 	 In one embodiment, the AH peptide-immobilization sub- 
those which are flowable, can be treated with an AH peptide 25 strate is a lumen surface of a tubing, which may be any 
by contacting the biological solution with a surface having 	 conduit or means which provides fluid communication 
immobilizedAH peptide. Thus the disclosure provides a sub- 	 between containers, such as containers for dispensing bio- 
strate having an immobilized AH peptide on at least one 	 logical fluids. Further the AH peptide-immobilization sub- 
surface such that 	 strates can include seals, valves, clamps, transfer leg closures, 
In other embodiments, methods for disinfecting whole so and the like which maybe used in connection with delivery of 
blood or blood products are provided which include the steps 	 blood or blood product to a subject. 
of providing a disinfectant composition of a disinfecting con- 	 A number of additional containers may be in communica- 
centration of amphipathic a-helix (AH) polypeptides and a 	 tion with the biological fluid processing system, and can be 
diluent, and then mixing whole blood or blood product with 	 utilized to define different flow paths. For example, an addi- 
the disinfecting composition for a length of time sufficient to 35 tional satellite bag containing physiological solution may be 
inactivate enveloped viruses having a diameter of less than 	 placed in communication with the biological fluid processing 
about 250 mn that may be present in the blood or blood 	 system. 
product. Mixing a disinfectant composition with blood or 	 AH peptides can also be used to provide for viral inactiva- 
blood products can be performed by simply combining the 	 tion of tissues and organs used for transplantation. This can be 
blood or blood product and disinfectant composition in a 4o accomplished by contacting the tissue or organ with an AH 
suitable container with light agitation to assure sufficient 	 peptide (e.g., by perfusion with an AH peptide-containing 
interaction between the blood and disinfectant composition. 	 solution) in an amount effective to reduce infection enveloped 
Suitable containers include but are not limited to blood col- 	 viruses that may be present in the tissue or organ, where the 
lection bags and blood storage apparatus. It may be desirable 	 enveloped viruses are less than about 250 nm in diameter. 
to use automated cell washing equipment known in the art. 45 	 AH peptides can also be used similarly to antibacterial 
After the blood or blood product is disinfected, the AH pep- 	 compositions (e.g., PURELL®, alcohol, and the like) to pro- 
tide may be optionally separated from the treated composi- 	 vide for disinfection of a biological or non-biological surface. 
tion, providing blood or blood product which is safe and 
	
Biological surfaces include skin (e.g., hands, site being 
effective for therapeutic use. Alternatively, it may be accept- 	 prepped for surgery, etc.). In these contexts AH peptides can 
able to maintain AH peptide in the treated blood. Such meth-  5o be administered in the form of formulated as topical creams, 
ods can be similarly applied for other flowable biological 	 ointments, lotions, gels, powders, liquids, solids, detergents 
materials, such as plasma or plasma products, including 	 or soaps. Non-biological surfaces (e.g., countertops, medical 
plasma protein fractions. 	 instruments, and the like) can be treated with AH peptide- 
The present disclosure also provides methods of disinfect- 	 containing formulations, which can take the form of, for 
ing a material especially a flowable material, using a substrate 55 example, sprays, saturated towelettes, saturated sponges, and 
having immobilized AH peptide. In this embodiment, AH 	 the like. 
peptides are immobilized on a substrate surface in a manner 	 In some embodiments, methods for reducing viral con- 
that maintains the ability of the AH peptide to disrupt a viral 	 tamination from medical devices, involve contacting the 
envelope. Exemplary methods include methods that provide 	 medical device with a composition containing one or more 
for non-covalent or covalent immobilization to a substrate 6o AH peptides, where theAH peptides are present in an amount 
surface, where the substrate may be solid or semi-solid. 	 sufficient to inactivate an enveloped virus where theAH pep- 
Where the substrate is semi-solid and/or porous, the AH 	 tides are present in an amount sufficient to disrupt enveloped 
peptide may be immobilized on any solvent-accessible or 	 virus that may be present in or on the medical device, where 
air-accessible surface. Methods for immobilizing AH pep- 	 the enveloped viruses are less than about 250 mn in diameter. 
tides can include coating, spraying, stamping, and the like. 65 The method may further include removing AH peptides from 
Covalent attachment to a surface can be accomplished by, for 	 the medical device. Examples of medical devices include 
example, attachment of an AH peptide through a chemically 	 those employed by a doctor, nurse, medical technician such as 
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one who collects blood or blood products, or dentist (and as 	 peptide with the material to be treated under a temperature 
such "medical device" is meant to encompass "dental 
	
20° C. or greater, 25° C. or greater, or 30° C. or greater can 
device"). 	 provide for enhanced efficiency of viral lysis, e.g., so as to 
The term "medical device" is intended to mean any tool 	 mediate lysis of at least 70%, at least 75%, at least 80%, at 
employed in the checking, cleaning, and/or collection of fluid 5 least 85% at least 90% or at least 95% of viral particles in a 
from or medical intervention of an animal or human body. 	 starting population. 
Such tools include, without limitation, surgical instruments 	 The suitable temperature used will be selected so as to be 
such as, but not limited to, probes, scalpels, clamps, forceps, 	 compatible with the materials to be disinfected/sterilized. For 
needles, suction devices for removing saliva or blood includ- 	 example, where the material is a biological material, such as 
ing all nozzles, seals, tubing, filters, containers and reservoirs io blood or component thereof, the blood or component thereof 
therein, endoscopes, optical fibers, transducers, wire, surgical 	 can be contacted with the AH peptide under a temperature of 
loops, and in-line and out-line tubing and filters through 
	
20° C. or greater, 25' C. or greater, or 30° C. or greater. pH and 
which blood or blood product is passed prior to delivery to an 	 osmolality can also be adjusted as discussed previously 
individual and/or at the point of collection from an individual. 	 herein provided that these conditions are consistent with 
Such medical devices can also serve as an AH peptide-immo-  15 maintaining the viability of the material to be disinfected/ 
bilization substrate, as discussed above. 	 sterilized. In addition, the concentration of one or more AH 
The disclosure also contemplate substrates that have been 	 peptides can also be adjusted to facilitate efficient lysis of 
treated with an AH peptide, which substrates may have 	 enveloped virus in the context of disinfectant/sterilization 
residual AH peptide, and may further have residual material 	 uses. For example, concentrations of about 1 µM, 2 µM, 3 µM, 
resulting from disruption of viral envelopes. In one embodi-  20 4 µM, 5 µM, 6 µM, 7 µM, 8 µM, 9 µM, 10 µM, 11 µM, 12 µM, 
ment, the substrate is other than a cell culture dish or vial (e.g., 	 13 µM, 14 µM, or 15 µM can be utilized. In some embodi- 
such as used in a research laboratory setting). In some 	 ments, an increase in the concentration of the AH peptide 
embodiments the material has a surface that contains immo- 	 provides for an enhanced activity of the AH peptide in facili- 
bilized AH peptide, as discussed above. 	 tating lysis of enveloped virus. 
Also contemplated, are methods for reducing viral con-  25 	 Use in Antiviral Therapy 
tamination of water or water containers such as found in 	 AH peptides can be used in antiviral therapy methods to 
swimming pools, hot-tubs, Jacuzzis, baths, and whirlpool 	 treat any subject having, suspected of having, or susceptible 
baths, air-conditioners and humidifiers, involving contacting 	 to infection by an enveloped virus, especially an enveloped 
the water or water container with a composition with an AH 	 virus having an average particle diameter of less than 250 mn 
peptide, where the AH peptides are present in an amount 30 or less than 110 mu. Such subjects include human and non- 
sufficient to disrupt enveloped virus that may be present, 	 human subjects, including without limitation, livestock (e.g., 
where the enveloped viruses are less than about 250 mn in 	 cattle, pigs, horses, sheep, etc.), poultry (e.g., chickens, tur- 
diameter. Such water and water containers can be those found 
	
keys, ducks, etc.), domestic pets (e.g., dogs, cats, etc.), and 
in the home, a hotel, spa or resort, office, or storage building. 	 zoo animals. A precise diagnosis of the viral infection need 
It should be noted that in all embodiments of disinfecting 35 not be necessary for use of the AH peptides. Instead, the 
methods using the AH peptides, the methods may be used for 	 clinician need only suspect that the viral infection be one that 
disrupting envelopes of an enveloped virus other than HCV. 	 is enveloped and having a viral particle diameter susceptible 
The disinfectingAH peptide-containing compositions may 	 to disruption by the AH peptide to be administered. Where 
include one or more additional compounds, as desired, with 
	
desired, such a diagnosis can be made based on, for example, 
the proviso these additional compound do not significantly 40 clinical signs and symptoms, diagnostic assay, and the like. In 
adversely affect activity of the AH peptide in disrupting viral 	 some embodiments, the viral infection to be treated is other 
envelopes of viruses of less than about 250 nm in diameter. 	 than an HCV viral infection. 
For example, such compounds may be antimicrobial (e.g., 	 A variety of methods for administering antiviral agents are 
antibacterial, antifungal) agents so as to enhance disinfection 	 known and include, without limitation, parenteral adminis- 
with respect to microorganisms. 	 45 tration (e.g., injection), aerosol administration, suppository, 
Sufficient periods of time for accomplishing disinfection 	 and, with proper design, oral administration. 
using the AH peptides as disclosed herein are primarily 	 Therapeutic compositions may include more than one AH 
dependent upon the choice of AH peptide and the material to 	 peptide. The precise formulations and modes of administra- 
be disinfected. It can also be appreciated that useful AH 	 tion of the AH peptide antiviral compositions will depend on 
peptide concentrations and periods of time for disinfecting 50 the nature of the antiviral agent, the condition of the subject, 
are interdependent. AH peptide-containing compositions 	 and the judgment of the practitioner. Design of such admin- 
include those that are not suitable for administration to a 	 istration and formulation is routine optimization generally 
subject, e.g., to a human subject. The phrase "notpharmaceu- 	 carried out without difficulty by the practitioner. 
tically acceptable" is meant to refer to a AH peptide-contain- 	 In addition to the AH peptides, combination therapies 
ing composition that contains, or contains at unacceptably 55 including other antiviral agents can be administered in con- 
high concentrations for pharmaceutical use, one or more 	 junction with AH peptides as disclosed herein. For example, 
compounds or solvents that are not suitable for administration 	 it may be desirable to administer an AH peptide in combina- 
to a subject by any route to effect an antiviral therapy. 	 tion with an agent such as interferon. 
Examples of such components include a surfactant (e.g., 	 As discussed previously herein, AH peptide formulation 
detergent), preservative, solvent (e.g., DMSO) disinfectant, 60 parameters can be varied to provide for enhanced activity of 
compound that provide for a scent, or other compound that is 	 the AH peptide in mediating viral lysis. 
not suitable for administration to a subject, e.g., a human, by 	 Conditions can be varied to suit the particular route of 
any route, e.g., by a parenteral route. 	 administration. For example, where an AH peptide is to be 
Use of AH peptides in the context of disinfection and/or 	 used in a topical formulation, it may be desirable to admin- 
sterilization can be carried out under conditions that provide 65 ister the AH peptide in a formulation having a pH of 7.5 or 
for enhanced activity of the AH peptide in mediating viral 
	
less. For example a pH of 7.5 or les s maybe utilized, e.g., a pH 
lysis as discussed above. For example, contacting the AH 	 of about 7.0, about 6.5, about 6.0, about 5.5, about 5.0, about 
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4.5, or about 4.0. In addition, where an AH peptide is to be 
used in a topical formulation it may be desirable to adjust the 
concentration of one or more salts in the formulation suchthat 
an osmotic pressure equivalent to that of a solution with a 
NaCl concentration of about 100 mM, about 150 mM, about 
200 mM, about 250 mM, about 300 mM, about 350 mM, 
about 400 mM, about 450 mM, about 500 mM, 550 mM, or 
about 600 mM is achieved. 
The concentration of one or more AH peptides can also be 
adjusted to facilitate efficient lysis of enveloped virus in the 
context of an antiviral therapy. For example, concentrations 
of about 1 µM, 2 µM, 3 µM, 4 µM, 5 µM, 6 µM, 7 µM, 8 µM, 
9 µM, 10 µM, 11 µM, 12 µM, 13 µM, 14 µM, or 15 µM can be 
utilized. In some embodiments, an increase in the concentra-
tion of theAH peptide provides for an enhanced activity of the 
AH peptide in facilitating lysis of enveloped virus. 
EXAMPLES 
The following examples are put forth so as to provide those 
of ordinary skill in the art with a complete disclosure and 
description of how to make and use the present invention, and 
are not intended to limit the scope of what the inventors regard 
as their invention nor are they intended to represent that the 
experiments below are all or the only experiments performed. 
Efforts have been made to ensure accuracy with respect to 
numbers used (e.g. amounts, temperature, etc.) but some 
experimental errors and deviations should be accounted for. 
Unless indicated otherwise, parts are parts by weight, 
molecular weight is weight average molecular weight, tem-
perature is in degrees Celsius, and pressure is at or near 
atmospheric. Standard abbreviations may be used, e.g., bp, 
base pair(s); kb, kilobase(s); pl, picoliter(s); s or sec, 
second(s); min, minute(s); h or hr, hour(s); aa, amino acid(s); 
kb, kilobase(s); bp, base pair(s); nt, nucleotide(s); i.m., intra-
muscular(ly); i.p., intraperitoneal(ly); s.c., subcutaneous(ly); 
and the like. 
Materials and Methods 
The Materials and Method described below were used in 
connection with Examples 1-4. Materials and Methods vary-
ing from those described below are discussed in the context of 
the specific examples. 
Amphipathic a-Helical (AH) and Non-Amphipathic Non-
Helical (NH) Peptides 
The amphipathic a-helical (AH) and non-amphipathic 
non-helical (NH) peptides were synthesized byAnaspec Cor-
poration (San Jose, Calif., USA). The NH peptide was 
designed so as to introduce three charged amino acids spaced 
at intervals along the predicted alpha-helix ofAH such that no 
sustained hydrophobic patch remained. The sequences ofAH 
and NH are H-Ser-Gly-Ser-Trp-Leu-Arg-Asp-Val-Trp-Asp-
Trp-Ile-Cys-Thr-Val-Leu-Thr-Asp-Phe-Lys-Thr-Trp-Leu-
Gln-Ser-Lys-Leu-Asp-Tyr-Lys-Asp-NH2 (SEQ ID NO: 89) 
and H-Ser-Gly-Ser-Trp-Leu-Arg-Asp-Asp-Trp-Asp-Trp-
Glu-Cys-Thr-Val-Leu-Thr-Asp-Asp-Lys-Thr-Trp-Leu-Gln-
Ser-Lys-Leu-Asp-Tyr-Lys-Asp-NH2 (SEQ ID NO: 90), 
respectively (the introduced charged amino acids are indi-
cated in bold). 
Small Unilamellar Vesicle Preparation 
Small unilamellar vesicles of 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) (Avanti Polar Lipids, 
Alabaster, USA) were prepared by the extrusion method. For 
QCM-D and AFM measurements, we have used Tris buffer: 
10 mM Tris [pH 7.5], 150 mM NaCl solution with 1 mM 
EDTA in 18.2 MQ-cm MilliQ water (MilliPore, Oregon, 
USA). Extruded unilamellar vesicles (referred to simply as 
vesicles) were prepared according to the protocol described 
34 
in Johnson et al. (2002) Biophys J. 83:3371-3379. Vesicles 
were generally prepared at a nominal lipid concentration of 
—5 mg/ml for QCM-D and AFM then subsequently diluted 
before experiments. Vesicles were generally used within one 
5 hour of preparation. 
Dynamic Light Scattering 
Dynamic light scattering (DLS) was performed by a 
90Plus Particle Size Analyzer and results analyzed by a digi-
tal autocorrelator software (Brookhaven Instruments Corpo- 
10 
ration, New York, USA). All measurements were taken at a 
scattering angle of 90° where the reflection effect is mini-
mized. All autocorrelation functions obtained were also ana-
lyzed by CONTIN and Non-Negatively Constrained Least 
Squares (NNLS) algorithms to check for multimodal distri-
butions. 
15 	 Quartz Crystal Microbalance-Dissipation (QCM-D) 
A Q-Sense D300 (Q-Sense AB, Gothenburg, Sweden) 
equipped with a QAFC 301 axial flow chamber was used to 
conduct QCM-D measurements. AT-cut crystals (Q-Sense) of 
14 mm in diameter with 50 mu thermally evaporated gold and 
20 TiO2 were used for all vesicle interactions and adsorptions. 
The crystal was driven at its resonance frequency of 5 MHz, 
and the frequency and dissipation changes for the three over-
tones at 15, 25, and 35 MHz were also monitored. To capture 
the characteristic dissipation, the drive circuit was short-cir- 
25 cuited andthe exponential decay of the crystal oscillationwas 
recorded. The temperature of the Q-Sense cell was set at 25.0° 
C. and accurately controlled by a Peltier element in the cell 
with fluctuation smaller than ±0.1 ° C. Each QCM crystal was 
treated with oxygen plasma at —75 watts for —5 minutes prior 
30 to measurements (March Plasmod Plasma Etcher, March 
Instruments, California, USA). 
QCM-D Sensor 
Quartz crystal microbalance-dissipation (QCM-D) 
devices were the first piezoelectric devices used in a detection 
35 application (Sauerbrey et al. (1959) Z. Physik 155: 206) and 
have played an important role in probing interfacial processes 
or acoustic properties of liquids. The operation of a QCM 
relies on the excitation into mechanical resonance induced by 
an electrical field across the quartz crystal with two metal 
40 electrodes on opposite sides of the quartz crystal plate. The 
acoustic waves generated in QCM devices are bulk transverse 
waves that travel in a direction perpendicular to the plate 
surfaces. Particle displacements at these surfaces are parallel 
to the surface (shear waves). The plate thickness d determines 
45 the wavelength X of the fundamental (n=1) and harmonic 
(n=3, 5.... ) resonances according to X=2d/n. 
Therefore: 
50 	 n - v 	
~1) f =n - fo= 2d 
where fo, f are the resonant frequencies of the fundamental 
55 mode (n=1) and the nth overtone (n=3, 5.... ), respectively, 
and v is the velocity of sound (v=3340 m/s in AT cut quartz). 
The resonant frequency of the fundamental mode is typi- 
cally between 5 and 20 MHz and increases as the plate thick- 
ness decreases. From these factors deduced a relationship for 
60 
determining of mass changes in thin films at the sensor sur- 
face, 
0f--2'fo'f
, 
	
.Om= —Cf -Am 	 (2) 
65 	 Pq uq 
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where Af, is the change of the resonant frequency and p, and 
rl, are the density and viscosity of the liquid in contact with 
the sensor surface, respectively. 
Atomic Force Microscopy (AFM) 
TheAFM experiments were carried out on a XE-100 (PSIA 
Sungnam, Korea) in contact mode and non-contact mode. 
Rectangular-shaped Si 3N4 cantilevers were used (ORC8C, 
Veeco, Santa Barbara, Calif.). The cantilevers had a force 
constant of k-0.05 N/m and average tip radius of 15 mu. All 
measurements were performed in a Tris buffer (150 mM 
NaCl, 10 mM Tris [pH 7.5], 1 mM EDTA) using an open 
liquid cell (PSIA Sungnam, Korea) with an injection tube. 
Images of vesicles were obtained both in the "contact" mode 
with an imaging force of less than 100 pN and with "non-
contact" mode in fluid. However, images presented in this 
manuscript were only obtained in the "non-contact" mode in 
fluid. The scan line speed was optimized between 0.3 Hz to 2 
Hz with a pixel number of 256x256, depending on the scan 
size. Images were recorded in height, amplitude, phase, and 
error modes. All measurements were done on the height 
images. All images shown were subjected to a first order 
plane-fitting procedure to compensate for sample tilt. The 
cross-sectional analysis was carried out on images subjected 
only to a first order plane-fitting procedure. Topographical 
and grain analyses of lipid vesicles and bilayers were per-
formed using the software XEI 1.5 supplied by PSIA (Sung-
nam, Korea). 
Example 1 
AH Peptides Ruptures Vesicles 
The ability of an amphipathic a-helix (AH) peptide to 
disrupt vesicles was demonstrated using an AH peptide 
derived from the N-terminus of the hepatitis C virus NSSA 
protein (Elezar et al. 2003 J. Virol77:6055-61). AH and NS 
peptides were produced by standard chemical synthetic meth-
ods. FIG. 1, Panels a-c provide schematic representations of 
the amphipathic alpha helix (AH) peptide (FIG. 1, Panel a) 
and a non-amphipathic, non-helical (NH) peptide (FIG. 1, 
Panel b), as well as a schematic illustrating creation of a 
bilayer on An and on TiO2 surfaces (FIG. 1, panel c). 
The left side of FIG. 1, Panel a shows a space-filling model 
of the AH peptide, which is derived from the first 31 amino 
5 acids of the hepatitis C virus (HCV) nonstructural protein 
NSSA's N-terminal alpha helix. The sequence of this AH 
peptide is SGSWLRDVWDWICTVLTDFK-
TWLQSKLDYKD (SEQ ID NO: 89). Hydrophobic and 
hydrophilic amino acids are shaded in white and grey, respec- 
io tively. The arrow indicates a 90 degree rotation about the 
y-axis, which leads to the image on the right side of FIG. 1, 
Panel a. The black/red circle around the AH illustrates the 
amphipathicity of this peptide. 
FIG. 1, Panel b provides an analogous depiction of the NH 
15 peptide that differs from AH by the substitution of charged 
amino acids for hydrophobic ones at three positions. The 
sequence of NH is SGSWLRDDWDWECTVLTD 
DKTWLQSKLDYKD (SEQ ID NO: 90) (where the three 
point mutations are indicated in bold and underlined). These 
20 substitutions were spaced at intervals along the predicted 
a-helix such that no sustained hydrophobic face remained. 
Circular dichroism measurements indicate that the helical 
structure of AH is disrupted by the mutations in NH. More-
over, the amphipathic nature of the peptide is disrupted, as 
25 illustrated in FIG. 1, Panel b, right side. 
The top left of FIG. 1, Panel c is a macroscopic idealization 
of vesicle adsorption on a gold quartz crystal. Zooming in, 
only the outer leaflet of a vesicle is illustrated. When the 
vesicle is exposed to AH peptides, the latter are speculated to 
30 first bind onto the outer leaflet and then open up the vesicle, as 
shown, exposing the inner leaflet to the solvent. It is hypoth-
esized that AH peptides induce pores, which then drive the 
disruption of the vesicle, which is accompanied in this system 
by the formation of bilayers. The result is a bilayer devoid of 
35 all vesicles. Note, for purposes of illustration, the bilayer is 
scaled down to the size of vesicles, which is why the sub-
strates appear larger. 
In order to systematically investigate the ability of AH 
peptides to rupture vesicles, synthetic vesicles were initially 
40 tested. The vesicles were made by extrusion through 30 nm 
polycarbonate etch-tracked (PEC) membranes on a gold sur-
face in the absence of the AH peptide, the peptide was then 
introduced to induce bilayer formation. It has been well docu-
mented that the high polarizability of the gold surface maxi- 
45 mizes the attractive potential, which is the driving force that 
enables vesicles to remain intact and stable on a gold support 
(Keller & Kasemo (1998) Biophys J. 75: 1397-1402; Keller et 
al. (2000) Phys Rev Lett 84: 5443-5446; Reimhult et al. 
(2002) Phys. Rev. E 66 (5 Pt 1), 051905; and Reimhult et al. 
50 (2003) Langmuir 19: 1681-1691). 
When vesicles adsorb, a large amount of trapped water 
exists within the intact vesicles as well as between vesicles 
adsorbed on the surface. This trapped water is able to dissi-
pate a large amount of energy (FIG. 2, Panel 2-1, sub-panel a), 
55 unlike the water that rests on top of a bilayer. Due to the 
viscoelastic nature of the films, the large energy dissipation 
(AD-8x10-6) leads to an underestimation of the layer thick-
ness using the Sauerbrey equation (Voinova et al. (2004) 
Spectroscopy-an International Journal 18: 537-544). This 
60 underestimate can be corrected by applying the viscoelastic 
model described by Voinova et al. (Voinova et al. (2004) 
Spectroscopy-an International Journal l8: 537-544; Voinova 
et al. (2002) Biosensors & Bioelectronics 17: 835-841; Voi-
nova et al. (1999) Physica Scripta 59, 391-396). After intro- 
65 ducing 0.05 mg•ml-i of theAH peptide to the vesicle layer on 
the gold surface (FIG. 2, Panel 2-1, sub-panel b), a large 
frequency decrease (-40 Hz) as well as a dissipation increase 
where At, is the change of the resonant frequency, p q is the 
density and µq is the shear modulus of the quartz crystal, 
respectively, Am is the mass per area and Cfis the sensitivity 
constant. This relation is valid for thin, rigid films with a 
uniform mass distribution. 
Due to this mass sensitivity a QCM sensor can be used for 
monitoring film thickness and mass deposition on the surface 
of a quartz crystal. With the same technique electrochemical 
or immunochemical mass deposition on a quartz crystal 
immersed in liquids can be detected (Aberl et al. (1994) 
Sensors and Actuators B-Chemical 18: 271-275; Andersson 
et al. (2003) J. Biomed Mater Res A 64: 622-629. Drost et al. 
(1998) Trends and New Applications of Thin Films 287-2: 
521-524; Fetchko & Stagljar (2004) Methods 32: 349-362; 
Fredriksson et al. (1998) J. Mater Sci Mater Med 9: 785-788). 
In the case of measurements in liquids, the additional effect 
of the acoustic properties of liquids on the sensor signal has to 
be considered. Kanazawa & Gordon, (1985) Anal. Chim. Acta 
175: 99-106, derived a relationship that expresses the change 
in oscillation frequency of a quartz crystal in contact with a 
fluid, 
A 	 1 	
(3) 
OJK --
Jt 
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(about 14x10-6) occur within two minutes. This result, 
although unexpected, provides a clue in our effort to under-
stand the molecular interactions that occur when the AH 
peptide and lipid bilayer interact. 
One possible explanation for this phenomenon is that the 5 
AH peptide first creates an instability on the vesicle surface 
by electrostatic interaction. This may lead to expansion of the 
vesicles (Gidalevitz et al. (2003) Proc Natl Acad Sci USA 
100: 6302-6307) as well as to the creation of microvilli 
(Mecke et al. (2005) Biophys J. 89,4043-4050; and Sato et al. io 
(1996) Biochim Biophys Acta 1285:14-20) (finger-like struc-
tures) on the outer leaflet of the vesicles (Bellomio et al. 
(2005) J Colloid Interface Sci 285: 118-124). This could 
explain both the large changes in frequency due to the pre-
sumed expansion of vesicles as well as the increase in dissi- 15 
pation ascribable to both expansion and microvilli structure. 
The most exciting results are that the final frequency shift 
relative to the initial state was 25.5 Hz±0.5, and the final 
dissipation value was only 0.08x10-6 (FIG. 2, Panel 2-1, 
sub-panel (b)), both values corresponding to a complete 20 
bilayer. According to the Sauerbrey equation, from which the 
bilayer thickness can be calculated, these QCM-D parameters 
indicate a transition of the vesicles to a thin and rigid bilayer 
film as a result of the action of the AH peptide. 
To further verify that the AH peptide, with its amphipathic 25 
a-helical structure, destabilized the vesicles, we repeated the 
experiments under the same conditions using a modified pep-
tide in which three charged amino acids were introduced into 
the hydrophobic face of the AH peptide (Elazar et al. (2003) 
J. Tirol. 77:6055-6061), disrupting its amphipathic nature and 30 
destroying its helical structure. As shown in FIG. 2, Panel 2-1, 
sub-panel (c), this non-helical peptide (termed NH peptide) 
does not destabilize intact vesicles since there are no changes 
in Af and AD after injection of the NH peptide. This indicates 
that the amphipathic helical structure is one of the essential 35 
characteristics in vesicle destabilization. 
While the QCM-D results demonstrate the process of 
kinetic changes from adsorption of vesicles to the formation 
of bilayers, we utilized atomic force microscopy (AFM) in 
order to confirm and directly display rupture of vesicles and 40 
bilayer formation by the destabilizing agent, the AH peptide. 
AFM examined the bare An surface as a control with Rq of 
1.13±0.21 mn (±S.E. n=8). Vesicles (0.1 mg/ml) were care-
fully added through the injection system, incubated for 30 
minutes, and thoroughly rinsed three times with Tris buffer. 45 
Intact vesicles were clearly identified by AFM and the aver-
age Rq increased to 2.49±0.32 nm (±S.E. n=8), as shown in 
FIG. 2, panel 2-1, sub-panel (e). 
The AFM images in FIG. 2, panel 2-1, sub-panel (f) show 
the effect of theAH peptide on the vesicles as a destabilizing 50 
agent, which we examined by injecting the peptide (0.05 
mg/ml) and incubating the solution for 2 hours prior to scan-
ning the images. These images clearly confirm the QCM-D 
data, indicating that vesicles ruptured as a result of the treat-
ment with AH peptide. The average Rq of 1.67±0.12 MU 55 
(±S.E. n15) indicated that the roughness became similar to 
the bare An surface (average Rq of 1.32±0.25 nm (±S.E. 
n=8)), as expected for a bilayer. Grain analysis identified no 
vesicle-like structures (P:50.001), indicating that theAH pep-
tides ruptured vesicles to form bilayers. These results corre- 60 
late with the QCM-D kinetic data shown in FIG. 2, Panel 2-1, 
sub-panel (b). An identical experiment has been done on TiO 2 
(FIG. 2, Panel 2-2) and has shown similar results. 
This example thus demonstrates that an AH peptide desta- 
bilizes and ruptures the leaflets of intact lipid vesicles. In 65 
addition, the ruptured vesicles to fuse and form planar bilay- 
ers on preferred solid substrates, such as gold and TiO 2 . 
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Example 2 
Interaction Between AH Peptides and Different Size 
Vesicles 
In general, formation of a bilayer through vesicle rupture 
depends on two major factors—vesicle-surface interaction 
and vesicle-vesicle interaction. For both these interactions, 
the outcome (intact vesicles or bilayers) depends on the elas-
tic properties and cohesive strength of the vesicles themselves 
(Reimhult et al. (2003) Langmuir 19 (5): 1681-1691; Reim-
hult et al. (2002) Journal of Chemical Physics 117 (16): 
7401-7404; Reimhult et al. (2002) Phys Rev E Stat Nonlin 
Soft Matter Phys 66, (5 Pt 1), 051905; Keller & Kasemo 
(1998) Biophys J75 (3): 1397-1402; and Keller et al. (2002) 
Phys Rev Lett 84 (23): 5443-6). 
In order to test the limitation of the rupturing strength of the 
AH peptide, the formation of bilayers on gold surfaces from 
vesicles of different sizes was studied. Larger vesicles 
(0-148 nm±1.4 mu) were first injected onto a gold surface 
(as in FIG. 4, Panel a), and then the AH peptide was applied 
(FIG. 4, panel b). However, under these conditions the AH 
peptide did not provide for complete rupture of vesicles 
extruded through 100 nm PEC membranes, which provides 
for production of vesicles having an average diameter of 
about 148 mu. This is presumably as a result of the significant 
difference in the radii of the curvature of the vesicles extruded 
through 100 nm PEC (about 75% of vesicles rupture) versus 
30 nm PEC, the latter of which have an average diameter of 
about 58 nm (approximately 100% of vesicle ruptured). The 
lack of formation of a complete bilayer is evidenced by a 
decrease of the final frequency by 50 Hz±2.5 (compared to 25 
Hz for a complete bilayer) and a maximum decrease of the 
dissipation shift to only 9x10-6 (compared to 0.08x10-6 for a 
complete bilayer) as shown in FIG. 4, panel (b). During the 
rupturing process, vesicles must possess a high line-tension in 
order for peptides to trigger destabilization and rupture of the 
vesicles, thus forming complete planar bilayers. 
These results suggest that the efficiency of AH peptides in 
rupturing vesicles decreases with increasing vesicle size. 
There may be a target size limit to the vesicle-destabilizing 
effect of the AH peptide related to the increased line tension 
associated with smaller diameter vesicles, which becomes 
less prominent as a function of increasing vesicle diameter. 
Based on the detergent binding properties of the amphipathic 
a-helical peptide, the location of its amino acids, and the 
findings of an NMR study (Perin et al. JBiol Chem (2004), 
and without being held to any particular theory, it is proposed 
that the mechanism of penetration into its target membrane is 
via the hydrophobic face of the helix within the cytoplasmic 
leaflet of the membranes. 
Example 3 
Detailed Description Regarding Bilayer Formation 
on a TiO2 Surface 
In order to prove that vesicle rupture is triggered by theAH 
peptide and is surface independent, TiO 2 surfaces, which are 
known to have higher polarizability and a higher isoelectric 
point than S'0 2 (pH5.5 vs. pH2.3) (Kataoka et al. (2004) 
Langmuir 20: 1662-1666), were used. This provides compat-
ible circumstances for the system, as these characteristics 
cause a low density of surface charges on TiO 2, and lead to 
intact vesicle deposition on TiO 2 surfaces. Similar experi-
ments were performed on a TiO 2 surface to those previously 
performed on theAu surfaces, as shown in FIG. 5, Panels a-e. 
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As hypothesized, vesicle rupture induced by the AH peptide 
leads to the formation of complete bilayers (see FIG. 5, Panel 
b). In addition, it is clearly demonstrated that in the case of 
larger vesicles extruded through the 100 mir PEC, the AH 
peptide did not completely rupture all the vesicles similar to 5 
what was observed on a gold surface (see FIG. 5, Panel e). 
Example 4  
40 
TABLE 1-continued 
13 pM 7.5 pM 3.75 pM 
PUPS 
100/0 100% 86% 75% 
75/25 100% 100% 89% 
70/30 100% 100% 100% 
10 	 7.5 100% 86% 75% 
6 100% 100% 95% 
5 100% 100% 100% 
4 100% 100% 100% 
Osmotic pressure between 
leaflets ofvesicles 
15 
150 mM NaCl 100% 86% 75% 
300 mM NaCl 100% 100% 89% 
450 mM NaCl 100% 100% 91% 
600 mM NaCl 100% 100% 95% 
Effect of AH Peptide on 148 Nm±1.4 Nm POPC 
Vesicles on a Ti02 Surface 
In a parallel experiment to that with QCM-D, AFM was 
used to test the ability of larger vesicles to fuse on a Ti0 2 
surface. FIG. 6, Panel b, demonstrates the vesicles extruded 
through 100 mir PEC membranes and deposited on the Ti0 2 
surface, which had an average Rq of 3.889 nm. Grain analysis 
identified 21 vesicles with an average diameter of 
132.75±5.55 nm (±S.E. n=21). The cross section of the area 
identified by the red line (measured from height images) 
shows the height of the vesicles to be approximately 20 nun. 
The AFM images indicate that vesicles ruptured as a result of 
treatment with the AH peptide at 0.05 mg/ml concentration, 
as shown in FIG. 6, Panels b and c. The average Rq became 
1.347 mir and the grain analysis identified 13 vesicles with an 
average diameter of 121.13±5.28 mir (±S.E. n=5), which 
correlates with the QCM-D data. 
Example 5 
Effect of Lysis Conditions on Efficiency of AH 
Peptide Mediated Lysis of Vesicles 
In order to determine the effect of various conditions on the 
efficiency of AH peptide mediated lysis of vesicles, AH pep-
tides were contacted to vesicles while varying the following 
parameters: temperature, lipid composition of vesicles, pH 
and osmotic pressure between leaflets of vesicles. Three con-
centrations ofAH peptide (13 µM, 7.5 µM and 3.75 µM) were 
tested for their ability to rupture vesicles having an average 
diameter of 75 mir while varying one of temperature, lipid 
composition of vesicles, pH and osmotic pressure between 
leaflets of vesicles from a standard set of conditions which 
included Tris buffer with NaCl at 150 mM, a temperature of 
25 deg. C., a pH of 7.5 and a vesicle composition of 
PC/PS=100/0. The PC/PS ratio refers to the weight percent-
age of POPC (1-Palmitoyl-2-Oleoyl-sn-Glycero-3-Phospho-
choline) relative to the weight percentage of DOPS (1,2-
Dioleoyl-sn-Glycero-3-Phosphoserine) used In the 
preparation of the vesicles. 
The results of the above experiments are shown in FIGS. 
7-10 and summarized in Table 1 below (%_% of vesicles 
ruptured as calculated using linear Sauerbrey model or equa-
tion described previously herein). Data is based on measure-
ments made using a Q-Sense E-4, multiple channel system 
(Q-Sense AB, Gothenburg, Sweden). 
Vesicles were prepared such that the inner compartment of 
the vesicle contained approximately 150 mM NaCl. 
TABLE 1 
13 pM 	 7.5 pM 	 3.75 pM  
20 As indicated above, when lower concentrations of AH 
peptide were used, varying conditions of temperature, lipid 
composition of vesicles, pH or osmotic pressure between 
leaflets of vesicles significantly altered the efficiency of the 
25 AH peptide mediated lysis of vesicles. For example, by 
increasing the temperature from 25 deg. C. to 30 deg. C. while 
using AH peptide at a concentration of 3.75 µM, vesicle lysis 
was increased from 75% to 100%. A similar effect was seen 
when the pH was decreased from 7.5 to 5 or 4 while using 3.75 
30 µM AH peptide. In addition, by increasing osmotic pressure 
between leaflets of vesicles through an increase in NaCl con-
centration from 150 mM to 600 mM, while using AH peptide 
at a concentration of 3.75 µM, vesicle lysis was increased 
from 75% to 95%. 
35 
Example 6 
Infectivity Assays Demonstrating AH 
Peptide-Mediated Disruption of Virus Particles for 
40 	 Small (HCV) but not Large (Vaccinia) 
Lipid vesicles represent a widely-used model for envel-
oped viruses. In order to demonstrate that AH peptides have a 
similar disruptive effect on the lipid envelopes of viruses, 
45 inoculums of HCV (avg. particle diameter of 50 nun) and 
Vaccinia virus (avg. particle diameter of 360 nm), were 
treated with either AH or control NH peptides according to 
the following protocol. 
Infectious viral stocks of HCV and Vaccinia virus were 
50 prepared as described previously (Elazer et al. (2003) Tirol. 
77:6055-61; and Sklan et al. (2007) J. Vrol. 81:11096-105). 
Peptides were reconstituted in water at a concentration of 
0.26 mM and stored at —80° C. Peptides were diluted in serum 
free medium containing 300 focus-forming units (FFU) of 
55 HCV or 50 plaque forming units (PFU) of Vaccinia virus to a 
final concentration of 13 µM and incubated at room tempera- 
ture for 0.5 h. The virus-peptide mixtures were then used to 
infect Huh 7.5 cells in a 96-well plate for HCV or CVl cells 
in 6 well plates for Vaccinia virus. After adsorption for 2 h at 
6o 37° C., the inocula were removed and fresh growth medium 
was added to the cells for 3 days. Huh 7.5 cells were then fixed 
with 4% formaldehyde and immunostained with primary 
antibody against HCV structural protein core (Matto et al. 
(2004) J. Vrol78:12047-53), and secondary antibody conju- 
65 gated to Alexa 594TM. The number of HCV-positive foci was 
counted by fluorescence microscopy. Vaccinia virus plaques 
were counted following cell fixation and staining with crystal 
Temperature 
25 	 100% 	 86% 	 75% 
27.5 	 100% 	 96% 	 86% 
30 	 100% 	 100% 	 100% 
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violet. Results are expressed as a percentage of the infectivity 
associated with the non-peptide treated control inoculum. 
As shown in FIG. 11, AH, but not NH, peptide treatment 
dramatically reduced the infectivity of HCV particles (avg. 
particle diameter of 50 mu). By contrast, analogous experi- 5 
ments performed with vaccinia virus (avg. particle diameter 
of 360 mu) exhibited little AH peptide-induced disruption of 
infectious virus particles (see FIG. 11). 
These results demonstrate that when present in an isolated, 
non-natural context, the AH peptide is a potent mediator of 10 
lipid vesicle and lipid membrane-bound virus particle lysis. 
The efficiency of this activity exhibits a size dependence that 
falls within the range of a wide array of medically-important 
viruses. 
15 
Example 7 
Further Characterization of Size-Dependent AH 
Peptide-Mediated Lysis 
20 
Additional experiments were conducted as described 
below in order to further characterize the size-dependent AH 
peptide-mediated lysis of vesicles. In order to capture the 
vesicle lysis potency of the AH peptide, we constructed a 
biomimetic, self-assembled intact vesicle platform on a gold- 25 
coated quartz crystal using a detection system with nano-
mass range precision. This technique measures not only the 
quantitative binding mass, but also the viscoelasticity of the 
adlayer. 
Materials and Methods 	 30 
Quartz Crystal Microbalance-Dissipation (QCM-D) 
Adsorption kinetics and the properties of the adsorbed 
layer were studied using a Q-Sense E-4, multiple channel 
system (Q-Sense AB, Gothenburg, Sweden). Note that this 
system is different than that used for Examples 1-4 above. 35 
The samples are introduced using a peristaltic pump with flow 
rate of 0.1 ml/min. AT-cut gold crystals (Q-Sense) of 14 mm 
in diameter with 50 nm thermally evaporated gold were used 
for the vesicle interaction and adsorption experiments 
described below. Each QCM crystal was treated with oxygen 40 
plasma at —80 watts for —3 minutes prior to measurements 
(March Plasmod Plasma Etcher, March Instruments, Califor-
nia, USA). The crystal was initially driven near its resonance 
frequency as indicated by a maximum in the current. To 
capture the characteristic dissipation, the drive circuit was 45 
short-circuited and the exponential decay of the crystal oscil-
lation was recorded and analyzed, yielding the frequency and 
dissipation changes at 5, 15, 25, 35, 45, 55 and 65 MHz. The 
temperature of the Q-Sense cell was set at 25.0° C. and 
accurately controlled by a Peltier element in the cell with 50 
fluctuation smaller than ±0.05° C. All experiments were 
repeated at least three times, with a standard deviation of less 
than I%. 
Small Unilamellar Vesicle Preparation 
Vesicles of 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho- 55 
choline (POPC) (Avanti Polar Lipids, Alabaster, USA) with 
different size distributions were prepared by the combination 
of freeze-thaw cycles and extrusion method. Throughout the 
experiments, we used a Tris buffer (10 mM Tris, pH 7.5 and 
150 mM NaCI) in 18.2 MQ-cm MilliQ water (MilliPore, 60 
Oregon, USA). Extruded vesicles (referred to simply as 
vesicles) were prepared in the following manner. Lipid films 
were prepared by first drying the as-supplied lipids dissolved 
in chloroform under a gentle stream of nitrogen at room 
temperature. Then the resulting lipid film was stored under 65 
vacuum for at least 5 hours in order to remove residual chlo-
roform. Vesicles were prepared by first swelling the lipid film  
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in aqueous solution then vortexing periodically for 5 min. The 
resulting vesicle solutions were subsequently sized by a mini 
extruder (Avanti Polar Lipids, Alabaster, USA) through poly-
carbonate membranes with nominal sizes of 1000-mu, 400-
mu, 200-nm, 100-nm, 50-nm and 30-nm pores. Vesicles were 
generally prepared at a nominal lipid concentration of —5 
mg/ml then subsequently diluted before experiments. 
Vesicles were generally used within a day of preparation. 
Peptides 
Amphipathic a-helical peptides (AH) and non-amphip-
athic non-helical peptides (NH) were synthesized byAnaspec 
Corporation (San Jose, Calif., USA). Whereas theAH peptide 
is helical with an extended hydrophobic domain, NH peptides 
were designed to introduce three charged amino acids (under-
lined). The sequences of AH and NH peptide are H-Ser-Gly-
Ser-Trp-Leu-Arg-Asp-Val-Trp-Asp-Trp-Ile-Cys-Thr-Val- 
Leu-Thr-Asp-Phe-Lys-Thr-Trp-Leu-Gln-Ser-Lys-Leu-NH2 
(SEQ ID NO: 32) and H-Ser-Gly-Ser-Trp-Leu-Arg-Asp-
Asp-Trp-Asp-Trp-Glu-Cys-Thr-Val-Leu-Thr-Asp-
Asp-Lys-Thr-Trp-Leu-Gln-Ser-Lys-Leu-NH2 (SEQ ID NO: 
91T, respectively. 
Results 
Two distinct binding kinetics and viscoelastic behaviors 
were identified, as a function of deposited vesicle size: a) the 
formation of a rigid bilayer by vesicle rupture via interaction 
withAH peptide (FIG. 12, Panels A and B), and b) AH peptide 
binding on intact vesicles that remain as a stable layer (FIG. 
12, Panels C and D). 
In addition two distinct potencies of the AH peptide were 
identified: a) a complete rupture and bilayer formation for 
vesicles with an average size range from 54 nm to 72 nm, and 
b) for vesicles with an average size distribution greater than 
90 nm a reduced potency, such that the AH peptides do not 
completely rupture vesicles. Without intending to be bound 
by any particular theory, it is presumed that this is a result of 
the significant difference in the radii of the vesicle curvatures 
of average size distribution of 55 nm versus 95 nm. The lack 
of formation of a complete bilayer from the larger vesicles is 
evidenced by rupturing percent decrease from 99% to 12% 
(FIG. 13). This is demonstrated by a decrease of the final 
frequency by 125±12 Hz (compared to 25 Hz for a complete 
bilayer) and a maximum decrease of the dissipation shift to 
only 23x 10-6 (compared to 0.08x 10' for a complete bilayer) 
as shown in FIG. 12. Moreover, the ability of the AH peptide 
to induce the lysis of vesicles further lessened when the 
average vesicle size distribution became greater than 150 mu, 
as shown by the AH peptide binding on vesicle assemblies 
with resulting increase in total bound mass (FIG. 12, Panels C 
and D; and FIG. 13). The negative values for percent ruptur-
ing of vesicles having an effective diameter of about 250 nm 
to about 300 nm are a result of the frequency values measured 
upon binding of the AH peptide on vesicle assemblies. 
Example 8 
Viscoelastic Modeling for Two Different Regions of 
a Biomimetic Intact Vesicle Platform Induced by 
Interactions with AH Peptides Derived from 
Hepatitis C Virus 
In order to gain insight into the structural changes of the 
biomimetic platform on the solid support shown in FIG. 12. 
The Voigt-Voinova model was employed to evaluate the 
experimentally measured Af and AD for two different plat-
forms (intact vesicle radius —60 nm and intact vesicle radius 
—300 mu). Briefly, the Voigt-Voinova model treats a biomi-
metic platform as a single Voigt element and the quartz crystal 
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is assumed to be purely elastic, and the surrounding solution 
is assumed to be purely viscous and Newtonian. Further, the 
thickness and density of the platform are assumed to be uni-
form with no slip between the platform and the crystal during 
shearing. Since the platform is represented with a homoge-
neous film on the crystal using four unknown parameters (pP, 
tP, µP, 'qP) and above the platform is a semi-infinite bulk 
liquid (p1, rl1), overtones were fitted to this model using the 
commercial program, Q-tools software (Q-Sense AB). 
QCM-D E4 has multiple channels that allows for concur-
rent measurements of Af and AD at the first, third, etc., over-
tone (n=1, 3.... ; i.e., f ~=5 MHz, 15 MHz.... ) up to n=13 to 
obtain the resonant frequencies, fir — I, fir-3, etc., and the 
corresponding dissipation values, Dn=1, Dn=3, etc., with a 
repetitionrate of —1 Hz. Sincethe linear relationship between 
the adsorbed mass and the change in frequency (Sauerbrey 
model) is not necessarily valid for viscoelastic films, which 
exhibit additional energy dissipations as well as frequency-
(overtone) dependent responses, this type of information is 
very important in understanding complex biomembrane 
research. 
The adsorption kinetics of intact vesicles with different 
radii were followed and then AH peptides were added. This 
allowed for analysis of the characteristic kinetics of the intact 
vesicle transformation to a complete bilayer on a pure gold 
solid substrate resulting from the addition of an AH peptide. 
The simultaneous measurements of changes in frequency, 
Afn, and energy dissipation, ADn, obtained at four different 
overtones (n=1 for the fundamental and 3, 5, 7, 9, 11, and 13 
for the overtones) were determined as a function of time. By 
employing the Uoigt model, it is possible to obtain measure-
ments of two or more harmonics. The Sauerbrey and Uoigt 
models were employed to calculate the thickness for the 
entire range of kinetic measurements demonstrating that for a 
"rigid" bilayer of —5 mu, the Sauerbrey model severely under-
estimates the thickness of the viscoelastic intact vesicle plat- 
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form (-22 mu), as opposed to the more accurate Uoigt model 
(-45 mu). The characteristic shear modulus (µP) and viscos-
ity (ql?) increased as thickness decreased. In other words, 
these two physical parameters confirmed that the platform 
5 had been changed from soft intact vesicles to a bilayer. 
In marked contrast, when biomimetic, self-assembled 
intact vesicles with diameter —300 mu were created, no vis-
coelastic changes were observed in the platform due to inter-
actions with the AH peptide. The stability of the frequency 
10 and dissipation of the bare gold crystal over 600 seconds was 
verified. Upon the addition of a vesicle solution (0.1 mg/ml), 
a rapid mass uptake was observed followed by a decrease in 
QCM-D frequency, reaching saturation. Note that the Sauer-
brey model predicts that these normalized frequency changes 
15 should be independent of overtone, which is not observed 
experimentally. This adsorption process is accompanied by 
an increase in AD, reaching saturation. The vesicles were 
saturated for 3000 seconds, and subsequently, theAH peptide 
was introduced. An initial binding and a large subsequent 
increase in At, decrease in AD„ was detected. In contrast 
20 to the vesicle to bilayer transformation case, AH bound to the 
intact vesicle platform and stabilized within 600 sec. This 
view was also confirmed by the Sauerbrey and Uoigt thick-
ness calculations. As AH peptides bind on the intact vesicle 
25 platform, due to high energy dissipation change, the Uoigt 
thickness dramatically increases, more so than does the 
Sauerbrey thickness. In addition, the characteristic shear 
modulus (µP) and viscosity ( ,q,) either does not change or 
slightly decreases, as compared with the vesicle-bilayer 
30 
transformation platform case. 
These results show two distinct kinetics depending on the 
radii of the intact vesicles: a) for intact vesicles less than —60 
mu, the AH peptide promotes rupturing to form a bilayer; b) 
for intact vesicles larger than —300 mu, the AH peptide does 
35 not promote rupturing, but rather binds on the intact vesicle 
platform. The platform can therefore be used as an effective 
means of detecting interactions with AH peptides. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 91 
<210> SEQ ID NO 1 
<211> LENGTH: 14 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 4 
<223> OTHER INFORMATION: X is charged or polar residue, such as R, H, W, 
or Y, especially a positively charged residue such as 
R, K or H 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 5 
<223> OTHER INFORMATION: X is any amino acid residue, and can be a 
residue other than an positively charged residue, e.g., D, 
I, or T, particularly negatively charged residue 
such as D or E 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 6 
<223> OTHER INFORMATION: X is other than a charged residue, and can be a 
nonpolar (hydrophobic) residue, such as V or I 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 7 
<223> OTHER INFORMATION: X is a nonpolar (hydrophobic) residue, such as 
W or V 
<220> FEATURE: 
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<221> NAME/KEY: VARIANT 
<222> LOCATION: 8 
<223> OTHER INFORMATION: X is a charged (e.g., negatively charged) or 
polar, uncharged residue, such as D, E, or N, 
particularly a negatively charged residue such as 
D or E 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 10 
<223> OTHER INFORMATION: X is other than a charged residue, and can be a 
nonpolar (hydrophobic) residue such as I or V 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 11 
<223> OTHER INFORMATION: X is polar, uncharged residue, nonpolar 
(hydrophobic) residue, or negatively charged 
residue, such as C or L or E, particularly a 
polar, uncharged residue, nonpolar (hydrophobic) 
residue, such as C or L 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 12 
<223> OTHER INFORMATION: X is a polar, uncharged residue, a nonpolar 
(hydrophobic) residue, or a positively charged 
residue, such as T, S, I , or H, particularly a 
polar, uncharged residue such as T 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 13 
<223> OTHER INFORMATION: X is a nonpolar (hydrophobic) residue, such as 
V, I or W 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 14 
<223> OTHER INFORMATION: X is C or L 
<400> SEQUENCE: 1 
Ser Trp Leu Xaa Xaa Xaa Xaa Xaa Trp Xaa Xaa Xaa Xaa Xaa 
1 	 5 	 10 
<210> SEQ ID NO 2 
<211> LENGTH: 14 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 2 
Ser Trp Leu Arg Asp Val Trp Asp Trp Ile Cys Thr Val Leu 
1 	 5 	 10 
<210> SEQ ID NO 3 
<211> LENGTH: 14 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 3 
Ser Trp Leu Arg Asp Val Trp Asp Trp Val Cys Thr Ile Leu 
1 	 5 	 10 
<210> SEQ ID NO 4 
<211> LENGTH: 14 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 4 
Ser Trp Leu Arg Asp Ile Trp Glu Trp Val Leu Ser Ile Leu 
1 	 5 	 10 
<210> SEQ ID NO 5 
<211> LENGTH: 14 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
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<400> SEQUENCE: 5 
Ser Trp Leu Arg Ile Ile Trp Asp Trp Val Cys Ser Trp Cys 
1 	 5 	 10 
<210> SEQ ID NO 6 
<211> LENGTH: 14 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 6 
Ser Trp Leu Arg Thr Ile Trp Asp Trp Val Cys Ser Val Cys 
1 	 5 	 10 
<210> SEQ ID NO 7 
<211> LENGTH: 14 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 7 
Ser Trp Leu His Asp Ile Trp Asp Trp Val Cys Ile Val Cys 
1 	 5 	 10 
<210> SEQ ID NO 8 
<211> LENGTH: 14 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 8 
Ser Trp Leu Trp Asp Val Trp Asp Trp Val Leu His Val Leu 
1 	 5 	 10 
<210> SEQ ID NO 9 
<211> LENGTH: 14 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 9 
Ser Trp Leu Tyr Asp Ile Val Asn Trp Val Cys Thr Val Cys 
1 	 5 	 10 
<210> SEQ ID NO 10 
<211> LENGTH: 14 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 10 
Ser Trp Leu Arg Asp Ile Trp Asp Trp Val Cys Thr Val Cys 
1 	 5 	 10 
<210> SEQ ID NO 11 
<211> LENGTH: 14 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 11 
Ser Trp Leu Arg Asp Ile Trp Asp Trp Ile Cys Glu Val Leu 
1 	 5 	 10 
<210> SEQ ID NO 12 
<211> LENGTH: 21 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 12 
Leu Arg Asp Ile Trp Asp Trp Ile Cys Glu Val Leu Ser Asp Phe Lys 
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1 	 5 	 10 	 is 
Thr Trp Leu Lys Ala 
20 
<210> SEQ ID NO 13 
<211> LENGTH: 24 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 13 
Trp Leu Arg Asp Val Trp Asp Trp Ile Cys Thr Val Leu Thr Asp Phe 
1 	 5 	 10 	 15 
Lys Thr Trp Leu Gin Ser Lys Leu 
20 
<210> SEQ ID NO 14 
<211> LENGTH: 24 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 14 
Trp Leu Arg Asp Val Trp Asp Trp Val Cys Thr Ile Leu Thr Asp Phe 
1 	 5 	 10 	 15 
Lys Asn Trp Leu Thr Ser Lys Leu 
20 
<210> SEQ ID NO 15 
<211> LENGTH: 24 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 15 
Trp Leu Arg Asp Ile Trp Glu Trp Val Leu Ser Ile Leu Thr Asp Phe 
1 	 5 	 10 	 15 
Lys Asn Trp Leu Ser Ala Lys Leu 
20 
<210> SEQ ID NO 16 
<211> LENGTH: 24 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 16 
Trp Leu Arg Ile Ile Trp Asp Trp Val Cys Ser Val Val Ser Asp Phe 
1 	 5 	 10 	 15 
Lys Thr Trp Leu Ser Ala Lys Ile 
20 
<210> SEQ ID NO 17 
<211> LENGTH: 24 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 17 
Trp Leu Arg Thr Ile Trp Asp Trp Val Cys Ser Val Leu Ala Asp Phe 
1 	 5 	 10 	 15 
Lys Ala Trp Leu Ser Ala Lys Ile 
20 
<210> SEQ ID NO 18 
<211> LENGTH: 24 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
US 8,728,793 B2 
51 
	
52 
-continued 
<400> SEQUENCE: 18 
Trp Leu His Asp Ile Trp Asp Trp Val Cys Ile Val Leu Ser Asp Phe 
1 	 5 	 10 	 15 
Lys Thr Trp Leu Ser Ala Lys Ile 
20 
<210> SEQ ID NO 19 
<211> LENGTH: 24 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 19 
Trp Leu Trp Asp Val Trp Asp Trp Val Leu His Val Leu Ser Asp Phe 
1 	 5 	 10 	 15 
Lys Thr Cys Leu Lys Ala Lys Phe 
20 
<210> SEQ ID NO 20 
<211> LENGTH: 24 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 20 
Trp Leu Tyr Asp Ile Val Asn Trp Val Cys Thr Val Leu Ala Asp Phe 
1 	 5 	 10 	 15 
Lys Leu Trp Leu Gly Ala Lys Ile 
20 
<210> SEQ ID NO 21 
<211> LENGTH: 24 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 21 
Trp Leu Arg Asp Ile Trp Asp Trp Val Cys Thr Val Leu Ser Asp Phe 
1 	 5 	 10 	 15 
Arg Val Trp Leu Lys Ser Lys Leu 
20 
<210> SEQ ID NO 22 
<211> LENGTH: 25 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 22 
Ser Trp Leu Arg Asp Val Trp Asp Trp Ile Cys Thr Val Leu Thr Asp 
1 	 5 	 10 	 15 
Phe Lys Thr Trp Leu Gin Ser Lys Leu 
20 	 25 
<210> SEQ ID NO 23 
<211> LENGTH: 25 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 23 
Ser Trp Leu Arg Asp Val Trp Asp Trp Val Cys Thr Ile Leu Thr Asp 
1 	 5 	 10 	 15 
Phe Lys Asn Trp Leu Thr Ser Lys Leu 
20 	 25 
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<210> SEQ ID NO 24 
<211> LENGTH: 25 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 24 
Ser Trp Leu Arg Asp Ile Trp Glu Trp Val Leu Ser Ile Leu Thr Asp 
1 	 5 	 10 	 15 
Phe Lys Asn Trp Leu Ser Ala Lys Leu 
20 	 25 
<210> SEQ ID NO 25 
<211> LENGTH: 24 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 25 
Ser Trp Leu Arg Ile Ile Trp Asp Trp Val Cys Ser Trp Ser Asp Phe 
1 	 5 	 10 	 15 
Lys Thr Trp Leu Ser Ala Lys Ile 
20 
<210> SEQ ID NO 26 
<211> LENGTH: 25 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 26 
Ser Trp Leu Arg Thr Ile Trp Asp Trp Val Cys Ser Val Leu Ala Asp 
1 	 5 	 10 	 15 
Phe Lys Ala Trp Leu Ser Ala Lys Ile 
20 	 25 
<210> SEQ ID NO 27 
<211> LENGTH: 25 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 27 
Ser Trp Leu His Asp Ile Trp Asp Trp Val Cys Ile Val Leu Ser Asp 
1 	 5 	 10 	 15 
Phe Lys Thr Trp Leu Ser Ala Lys Ile 
20 	 25 
<210> SEQ ID NO 28 
<211> LENGTH: 25 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 28 
Ser Trp Leu Trp Asp Val Trp Asp Trp Val Leu His Val Leu Ser Asp 
1 	 5 	 10 	 15 
Phe Lys Thr Cys Leu Lys Ala Lys Phe 
20 	 25 
<210> SEQ ID NO 29 
<211> LENGTH: 25 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 29 
Ser Trp Leu Tyr Asp Ile Val Asn Trp Val Cys Thr Val Leu Ala Asp 
1 	 5 	 10 	 15 
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Phe Lys Leu Trp Leu Gly Ala Lys Ile 
20 	 25 
<210> SEQ ID NO 30 
<211> LENGTH: 25 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 30 
Ser Trp Leu Arg Asp Ile Trp Asp Trp Val Cys Thr Val Leu Ser Asp 
1 	 5 	 10 	 15 
Phe Arg Val Trp Leu Lys Ser Lys Leu 
20 	 25 
<210> SEQ ID NO 31 
<211> LENGTH: 24 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 31 
Ser Gly Ser Leu Arg Asp Ile Trp Asp Trp Ile Cys Glu Val Leu Ser 
1 	 5 	 10 	 15 
Asp Phe Lys Thr Trp Leu Lys Ala 
20 
<210> SEQ ID NO 32 
<211> LENGTH: 27 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 32 
Ser Gly Ser Trp Leu Arg Asp Val Trp Asp Trp Ile Cys Thr Val Leu 
1 	 5 	 10 	 15 
Thr Asp Phe Lys Thr Trp Leu Gin Ser Lys Leu 
20 	 25 
<210> SEQ ID NO 33 
<211> LENGTH: 27 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 33 
Ser Gly Ser Trp Leu Arg Asp Val Trp Asp Trp Val Cys Thr Ile Leu 
1 	 5 	 10 	 15 
Thr Asp Phe Lys Asn Trp Leu Thr Ser Lys Leu 
20 	 25 
<210> SEQ ID NO 34 
<211> LENGTH: 27 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 34 
Ser Gly Ser Trp Leu Arg Asp Ile Trp Glu Trp Val Leu Ser Ile Leu 
1 	 5 	 10 	 15 
Thr Asp Phe Lys Asn Trp Leu Ser Ala Lys Leu 
20 	 25 
<210> SEQ ID NO 35 
<211> LENGTH: 26 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 35 
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Ser Gly Ser Trp Leu Arg Ile Ile Trp Asp Trp Val Cys Ser Trp Ser 
1 	 5 	 10 	 15 
Asp Phe Lys Thr Trp Leu Ser Ala Lys Ile 
20 	 25 
<210> SEQ ID NO 36 
<211> LENGTH: 27 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 36 
Ser Gly Ser Trp Leu Arg Thr Ile Trp Asp Trp Val Cys Ser Val Leu 
1 	 5 	 10 	 15 
Ala Asp Phe Lys Ala Trp Leu Ser Ala Lys Ile 
20 	 25 
<210> SEQ ID NO 37 
<211> LENGTH: 27 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 37 
Ser Gly Ser Trp Leu His Asp Ile Trp Asp Trp Val Cys Ile Val Leu 
1 	 5 	 10 	 15 
Ser Asp Phe Lys Thr Trp Leu Ser Ala Lys Ile 
20 	 25 
<210> SEQ ID NO 38 
<211> LENGTH: 27 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 38 
Ser Gly Ser Trp Leu Trp Asp Val Trp Asp Trp Val Leu His Val Leu 
1 	 5 	 10 	 15 
Ser Asp Phe Lys Thr Cys Leu Lys Ala Lys Phe 
20 	 25 
<210> SEQ ID NO 39 
<211> LENGTH: 27 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 39 
Ser Gly Ser Trp Leu Tyr Asp Ile Val Asn Trp Val Cys Thr Val Leu 
1 	 5 	 10 	 15 
Ala Asp Phe Lys Leu Trp Leu Gly Ala Lys Ile 
20 	 25 
<210> SEQ ID NO 40 
<211> LENGTH: 27 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 40 
Ser Gly Ser Trp Leu Arg Asp Ile Trp Asp Trp Val Cys Thr Val Leu 
1 	 5 	 10 	 15 
Ser Asp Phe Arg Val Trp Leu Lys Ser Lys Leu 
20 	 25 
<210> SEQ ID NO 41 
<211> LENGTH: 26 
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<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 41 
Gly Ser Trp Leu Arg Asp Val Trp Asp Trp Ile Cys Thr Val Leu Thr 
1 	 5 	 10 	 15 
Asp Phe Lys Thr Trp Leu Gin Ser Lys Leu 
20 	 25 
<210> SEQ ID NO 42 
<211> LENGTH: 26 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 42 
Gly Ser Trp Leu Arg Asp Val Trp Asp Trp Val Cys Thr Ile Leu Thr 
1 	 5 	 10 	 15 
Asp Phe Lys Asn Trp Leu Thr Ser Lys Leu 
20 	 25 
<210> SEQ ID NO 43 
<211> LENGTH: 26 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 43 
Gly Ser Trp Leu Arg Asp Ile Trp Glu Trp Val Leu Ser Ile Leu Thr 
1 	 5 	 10 	 15 
Asp Phe Lys Asn Trp Leu Ser Ala Lys Leu 
20 	 25 
<210> SEQ ID NO 44 
<211> LENGTH: 25 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 44 
Gly Ser Trp Leu Arg Ile Ile Trp Asp Trp Val Cys Ser Trp Ser Asp 
1 	 5 	 10 	 15 
Phe Lys Thr Trp Leu Ser Ala Lys Ile 
20 	 25 
<210> SEQ ID NO 45 
<211> LENGTH: 26 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 45 
Gly Ser Trp Leu Arg Thr Ile Trp Asp Trp Val Cys Ser Val Leu Ala 
1 	 5 	 10 	 15 
Asp Phe Lys Ala Trp Leu Ser Ala Lys Ile 
20 	 25 
<210> SEQ ID NO 46 
<211> LENGTH: 26 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 46 
Gly Ser Trp Leu His Asp Ile Trp Asp Trp Val Cys Ile Val Leu Ser 
1 	 5 	 10 	 15 
Asp Phe Lys Thr Trp Leu Ser Ala Lys Ile 
20 	 25 
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<210> SEQ ID NO 47 
<211> LENGTH: 26 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 47 
Gly Ser Trp Leu Trp Asp Val Trp Asp Trp Val Leu His Val Leu Ser 
1 	 5 	 10 	 15 
Asp Phe Lys Thr Cys Leu Lys Ala Lys Phe 
20 	 25 
<210> SEQ ID NO 48 
<211> LENGTH: 26 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 48 
Gly Ser Trp Leu Tyr Asp Ile Val Asn Trp Val Cys Thr Val Leu Ala 
1 	 5 	 10 	 15 
Asp Phe Lys Leu Trp Leu Gly Ala Lys Ile 
20 	 25 
<210> SEQ ID NO 49 
<211> LENGTH: 26 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 49 
Gly Ser Trp Leu Arg Asp Ile Trp Asp Trp Val Cys Thr Val Leu Ser 
1 	 5 	 10 	 15 
Asp Phe Arg Val Trp Leu Lys Ser Lys Leu 
20 	 25 
<210> SEQ ID NO 50 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 50 
Ser Trp Leu Arg Asp Val Trp Asp Trp Ile Cys Thr Val Leu Thr 
1 	 5 	 10 	 15 
<210> SEQ ID NO 51 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 51 
Ser Trp Leu Arg Asp Val Trp Asp Trp Val Cys Thr Ile Leu Thr 
1 	 5 	 10 	 15 
<210> SEQ ID NO 52 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 52 
Ser Trp Leu Arg Asp Ile Trp Glu Trp Val Leu Ser Ile Leu Thr 
1 	 5 	 10 	 15 
<210> SEQ ID NO 53 
<211> LENGTH: 15 
<212> TYPE: PRT 
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<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 53 
Ser Trp Leu Arg Ile Ile Trp Asp Trp Val Cys Ser Trp Ser Asp 
1 	 5 	 10 	 15 
<210> SEQ ID NO 54 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 54 
Ser Trp Leu Arg Thr Ile Trp Asp Trp Val Cys Ser Val Leu Ala 
1 	 5 	 10 	 15 
<210> SEQ ID NO 55 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 55 
Ser Trp Leu His Asp Ile Trp Asp Trp Val Cys Ile Val Leu Ser 
1 	 5 	 10 	 15 
<210> SEQ ID NO 56 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 56 
Ser Trp Leu Trp Asp Val Trp Asp Trp Val Leu His Val Leu Ser 
1 	 5 	 10 	 15 
<210> SEQ ID NO 57 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 57 
Ser Trp Leu Tyr Asp Ile Val Asn Trp Val Cys Thr Val Leu Ala 
1 	 5 	 10 	 15 
<210> SEQ ID NO 58 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 58 
Ser Trp Leu Arg Asp Ile Trp Asp Trp Val Cys Thr Val Leu Ser 
1 	 5 	 10 	 15 
<210> SEQ ID NO 59 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 59 
Ser Trp Leu Arg Asp Val Trp Asp Trp Ile Cys Thr Val Leu Thr Asp 
1 	 5 	 10 	 15 
<210> SEQ ID NO 60 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 60 
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Ser Trp Leu Arg Asp Val Trp Asp Trp Val Cys Thr Ile Leu Thr Asp 
1 	 5 	 10 	 15 
<210> SEQ ID NO 61 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 61 
Ser Trp Leu Arg Asp Ile Trp Glu Trp Val Leu Ser Ile Leu Thr Asp 
1 	 5 	 10 	 15 
<210> SEQ ID NO 62 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 62 
Ser Trp Leu Arg Ile Ile Trp Asp Trp Val Cys Ser Trp Ser Asp Phe 
1 	 5 	 10 	 15 
<210> SEQ ID NO 63 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 63 
Ser Trp Leu Arg Thr Ile Trp Asp Trp Val Cys Ser Val Leu Ala Asp 
1 	 5 	 10 	 15 
<210> SEQ ID NO 64 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 64 
Ser Trp Leu His Asp Ile Trp Asp Trp Val Cys Ile Val Leu Ser Asp 
1 	 5 	 10 	 15 
<210> SEQ ID NO 65 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 65 
Ser Trp Leu Trp Asp Val Trp Asp Trp Val Leu His Val Leu Ser Asp 
1 	 5 	 10 	 15 
<210> SEQ ID NO 66 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 66 
Ser Trp Leu Tyr Asp Ile Val Asn Trp Val Cys Thr Val Leu Ala Asp 
1 	 5 	 10 	 15 
<210> SEQ ID NO 67 
<211> LENGTH: 16 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 67 
Ser Trp Leu Arg Asp Ile Trp Asp Trp Val Cys Thr Val Leu Ser Asp 
1 	 5 	 10 	 15 
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<210> SEQ ID NO 68 
<211> LENGTH: 17 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 68 
Ser Trp Leu Arg Asp Val Trp Asp Trp Ile Cys Thr Val Leu Thr Asp 
1 	 5 	 10 	 15 
Phe 
<210> SEQ ID NO 69 
<211> LENGTH: 17 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 69 
Ser Trp Leu Arg Asp Val Trp Asp Trp Val Cys Thr Ile Leu Thr Asp 
1 	 5 	 10 	 15 
Phe 
<210> SEQ ID NO 70 
<211> LENGTH: 17 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 70 
Ser Trp Leu Arg Asp Ile Trp Glu Trp Val Leu Ser Ile Leu Thr Asp 
1 	 5 	 10 	 15 
Phe 
<210> SEQ ID NO 71 
<211> LENGTH: 17 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 71 
Ser Trp Leu Arg Ile Ile Trp Asp Trp Val Cys Ser Trp Ser Asp Phe 
1 	 5 	 10 	 15 
Lys 
<210> SEQ ID NO 72 
<211> LENGTH: 17 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 72 
Ser Trp Leu Arg Thr Ile Trp Asp Trp Val Cys Ser Val Leu Ala Asp 
1 	 5 	 10 	 15 
Phe 
<210> SEQ ID NO 73 
<211> LENGTH: 17 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 73 
Ser Trp Leu His Asp Ile Trp Asp Trp Val Cys Ile Val Leu Ser Asp 
1 	 5 	 10 	 15 
Phe 
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-continued 
<210> SEQ ID NO 74 
<211> LENGTH: 17 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 74 
Ser Trp Leu Trp Asp Val Trp Asp Trp Val Leu His Val Leu Ser Asp 
1 	 5 	 10 	 15 
Phe 
<210> SEQ ID NO 75 
<211> LENGTH: 17 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 75 
Ser Trp Leu Tyr Asp Ile Val Asn Trp Val Cys Thr Val Leu Ala Asp 
1 	 5 	 10 	 15 
Phe 
<210> SEQ ID NO 76 
<211> LENGTH: 17 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 76 
Ser Trp Leu Arg Asp Ile Trp Asp Trp Val Cys Thr Val Leu Ser Asp 
1 	 5 	 10 	 15 
Phe 
<210> SEQ ID NO 77 
<211> LENGTH: 30 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 77 
Ser Gly Ser Trp Leu Arg Asp Val Trp Asp Trp Ile Cys Thr Val Leu 
1 	 5 	 10 	 15 
Thr Asp Phe Lys Thr Trp Leu Gin Ser Lys Leu Asp Tyr Lys 
20 	 25 	 30 
<210> SEQ ID NO 78 
<211> LENGTH: 27 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 4, 9, 	 11, 22 
<223> OTHER INFORMATION: X is A or F 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 5, 16, 	 23 
<223> OTHER INFORMATION: X is A or K 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 6 
<223> OTHER INFORMATION: X is A or N 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 7, 	 10, 	 13, 18 
<223> OTHER INFORMATION: X is A or S 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 8 
<223> OTHER INFORMATION: X is D, 	 I or S 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 12 
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-continued 
<223> OTHER INFORMATION: X is E or L 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 14 
<223> OTHER INFORMATION: X A, E, or W 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 15 
<223> OTHER INFORMATION: X is D or S 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 17 
<223> OTHER INFORMATION: X is A, S, or W 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 19 
<223> OTHER INFORMATION: X is D or L 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 20 
<223> OTHER INFORMATION: X is A or L 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 21 
<223> OTHER INFORMATION: X is A or W 
<400> SEQUENCE: 78 
Ser Gly Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1 	 5 	 10 	 15 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gin Ser Lys Leu 
20 	 25 
<210> SEQ ID NO 79 
<211> LENGTH: 23 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 79 
Gin Asp Val Leu Lys Glu Val Lys Ala Ala Ala Ser Lys Val Lys Ala 
1 	 5 	 10 	 15 
Asn Leu Leu Ser Val Glu Glu 
20 
<210> SEQ ID NO 80 
<211> LENGTH: 19 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 80 
Asp Val Arg Cys His Ala Arg Lys Ala Val Ala His Ile Asn Ser Val 
1 	 5 	 10 	 15 
Trp Lys Asp 
<210> SEQ ID NO 81 
<211> LENGTH: 28 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 81 
Ile Glu Gin Gly Met Met Leu Ala Glu Gin Phe Lys Gin Lys Ala Leu 
1 	 5 	 10 	 15 
Gly Leu Leu Gin Thr Ala Ser Arg His Ala Glu Val 
20 	 25 
<210> SEQ ID NO 82 
<211> LENGTH: 17 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
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-continued 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 1 
<223> OTHER INFORMATION: when x is present, x = L 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 2 
<223> OTHER INFORMATION: when x is present, x = R 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 11 
<223> OTHER INFORMATION: when x is present, x = V 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 12 
<223> OTHER INFORMATION: when x is present, x = L 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 13 
<223> OTHER INFORMATION: when x is present, x = T 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 14 
<223> OTHER INFORMATION: when x is present, x = D 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 15 
<223> OTHER INFORMATION: when x is present, x = F 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 16 
<223> OTHER INFORMATION: when x is present, x = K 
<220> FEATURE: 
<221> NAME/KEY: VARIANT 
<222> LOCATION: 17 
<223> OTHER INFORMATION: when x is present, x = T 
<400> SEQUENCE: 82 
Xaa Xaa Asp Val Trp Asp Trp Ile Cys Thr Xaa Xaa Xaa Xaa Xaa Xaa 
1 	 5 	 10 	 15 
Xaa 
<210> SEQ ID NO 83 
<211> LENGTH: 17 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 83 
Leu Arg Asp Val Trp Asp Trp Ile Cys Thr Val Leu Thr Asp Phe Lys 
1 	 5 	 10 	 15 
Thr 
<210> SEQ ID NO 84 
<211> LENGTH: 10 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 84 
Leu Arg Asp Val Trp Asp Trp Ile Cys Thr 
1 	 5 	 10 
<210> SEQ ID NO 85 
<211> LENGTH: 12 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 85 
Asp Val Trp Asp Trp Ile Cys Thr Val Leu Thr Asp 
1 	 5 	 10 
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<210> SEQ ID NO 86 
<211> LENGTH: 11 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 86 
Ser Trp Leu Arg Asp Val Trp Asp Trp Ile Cys 
1 	 5 	 10 
<210> SEQ ID NO 87 
<211> LENGTH: 28 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 87 
Leu Cys Leu Ala Gly Arg Gly Leu Gin Glu Ala Glu Gly Leu Leu Leu 
1 	 5 	 10 	 15 
Glu Leu Leu Ser Glu His His Pro Leu Leu Asp Val 
20 	 25 
<210> SEQ ID NO 88 
<211> LENGTH: 22 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 88 
Glu Leu Gly Phe Gin Pro Gly Leu Lys Val Ala Gin His Leu Ala Tyr 
1 	 5 	 10 	 15 
Pro Val Pro Asp Val Pro 
20 
<210> SEQ ID NO 89 
<211> LENGTH: 31 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 89 
Ser Gly Ser Trp Leu Arg Asp Val Trp Asp Trp Ile Cys Thr Val Leu 
1 	 5 	 10 	 15 
Thr Asp Phe Lys Thr Trp Leu Gin Ser Lys Leu Asp Tyr Lys Asp 
20 	 25 	 30 
<210> SEQ ID NO 90 
<211> LENGTH: 31 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 90 
Ser Gly Ser Trp Leu Arg Asp Asp Trp Asp Trp Glu Cys Thr Val Leu 
1 	 5 	 10 	 15 
Thr Asp Asp Lys Thr Trp Leu Gin Ser Lys Leu Asp Tyr Lys Asp 
20 	 25 	 30 
<210> SEQ ID NO 91 
<211> LENGTH: 27 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 91 
Ser Gly Ser Trp Leu Arg Asp Asp Trp Asp Trp Glu Cys Thr Val Leu 
1 	 5 	 10 	 15 
Thr Asp Asp Lys Thr Trp Leu Gin Ser Lys Leu 
20 	 25 
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What is claimed is: 
1. A method of inactivating an enveloped virus, the method 
comprising: 
contacting an enveloped virus having an average particle 
diameter of less than 150 nun with an amphipathic a-he-
lical (AH) peptide in an amount and under conditions 
effective to facilitate disruption of the viral envelope, 
with the proviso that the enveloped virus is other than 
hepatitis C virus (HCV), wherein theAH peptide is from 
the N-terminal alpha-helix of hepatitis C virus (HCV) 
nonstructural protein NSSA, 
wherein said contacting is effective to disrupt the viral 
envelope of the virus, thereby reducing infectivity of the 
virus. 
2. The method of claim 1, wherein the enveloped virus is 
present in a biological fluid. 
3. The method of claim 2, wherein the biological fluid is 
blood. 
4. The method of claim 3, wherein the biological fluid is 
extracorporeal. 
5. The method of claim 1, wherein said conditions include 
a pH of 7.5 or less. 
6. The method of claim 5, wherein said conditions include 
a pH of 7.0 or less. 
7. The method of claim 6, wherein said conditions include 
a pH of 6.5 or less. 
8. The method of claim 7, wherein said conditions include 
a pH of 6.0 or less. 
9. The method of claim 8, wherein said conditions include 
a pH of 5.5 or less. 
10. The method of claim 9, wherein said conditions include 
a pH of 5.0 or less. 
11. The method of claim 10, wherein said conditions 
include a pH of 4.5 or less. 
12. The method of claim 11, wherein said conditions 
include a pH of 4.0 or less. 
13. The method of claim 1, wherein said conditions include 
a temperature of 20° C. or greater. 
14. The method of claim 13, wherein said conditions 
include a temperature of 25° C. or greater. 
15. The method of claim 14, wherein said condition include 
a temperature of 30° C. or greater. 
16. A method for treating in vitro or ex vivo biological 
fluid, comprising: 
contacting an isolated biological fluid with an effective 
amount of an amphipathic a-helical (AH) peptide from 
the N-terminal alpha-helix of hepatitis C virus (HCV) 
nonstructural protein NSSA; 
wherein said contacting provides for disruption of an 
enveloped virus that may be present in the biological 
78 
fluid, wherein the enveloped virus has an average par-
ticle diameter of less than 150 nun and is other than 
hepatitis C virus. 
17. The method of claim 16, wherein said contacting is 
5 accomplished by mixing the biological fluid with a compo-
sition comprising the AH peptide. 
18. The method of claim 16, wherein the AH peptide is 
immobilized on a surface of a substrate. 
19. A method for decreasing a level of an enveloped virus 
10 
contaminating a material, the method comprising: 
treating a material with an effective amount of an amphi-
pathic a-helical (AH) peptide, wherein said treating is 
effective to disrupt at least 25% of enveloped viral par-
ticles that may be associated with the material, wherein 
the enveloped virus has an average particle diameter of 
15 less than 150 nun and is other than hepatitis C virus, 
wherein the AH peptide is from the N-terminal alpha-
helix of hepatitis C virus (HCV) nonstructural protein 
NSSA. 
20. The method of claim 19, wherein the material is a 
20 biological fluid. 
21. The method of claim 20, wherein the biological fluid is 
in a container. 
22. The method of claim 20, wherein the biological fluid is 
blood or a blood product. 
25 	 23. The method of claim 19, wherein the material is a 
biological tissue. 
24. The method of claim 23, wherein the biological tissue 
is an organ for transplant. 
25. The method of claim 22, wherein the blood product is 
30 plasma. 
26. The method of claim 19, further comprising removing 
all or a portion of the AH peptide and/or disrupted enveloped 
viral particle from the material after treating. 
27. The method of claim 1, wherein the AH peptide com- 
35 prises an amino acid sequence of the formula: 
SWLX iX2X3X4X5WXIXIX$XIX io (SEQID NO: 1), 
wherein X, is a charged residue or a polar residue; X z is any 
amino acid residue; X3 is other than a charged residue; 
X4 is a nonpolar residue; X 5 is a charged residue or a 
40 polar, uncharged residue; X 6 is other than a charged 
residue; X, is a polar, uncharged residue, a nonpolar 
residue, or a negatively charged residue; X $ is a polar, 
uncharged residue, a nonpolar residue, or a positively 
chargedresidue; X g is a nonpolar residue; andX, o is C or 
45 	 L. 
28. The method of claim 1, wherein the AH peptide com-
prises an amino acid sequence as set forth in any one of SEQ 
ID NOs:2-77. 
29. The method of claim 1, wherein the AH peptide has a 
50 length of from 14 amino acids to 30 amino acids. 
